656 results on '"Randomized controlled trial"'
Search Results
2. Statistical and Methodological Considerations for Randomized Controlled Trial Design in Physical Medicine and Rehabilitation.
- Author
-
Thakur, Bhaskar, Ayers, Gregory D., Atem, Folefac, DeClercq, Joshua J., and Jain, Nitin B.
- Subjects
- *
EXPERIMENTAL design , *PHYSICAL medicine , *FUNCTIONAL status , *CONTINUING education units , *EVIDENCE-based medicine , *HEALTH outcome assessment , *HEALTH status indicators , *RANDOMIZED controlled trials , *DRUGS , *QUALITY of life , *REHABILITATION , *PATIENT compliance - Abstract
Well-designed randomized controlled clinical trials assessing treatments in the field of physical medicine and rehabilitation are essential for evidence-based patient care. However, there are challenges unique to clinical trials in physical medicine and rehabilitation due to complex health interventions in this field. We highlight routinely encountered empirical challenges and provide evidence-based recommendations on statistical and methodological approaches for the design and conduct of randomized controlled trials. Some of the issues addressed include challenges with blinding treatment groups in a rehabilitation setting, heterogeneity in treatment therapy, heterogeneity of treatment effects, uniformity in patient-reported outcome measures, and effect on power with varying scales of information. Furthermore, we discuss challenges with estimation of sample size and power, adaption to poor compliance with treatment and missing outcomes, and preferred statistical approaches for longitudinal data analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Dry mouth in patients with a life-limiting condition or frailty: a study protocol for two intervention studies and a nested qualitative sub-study (the Dry mOuth Project, DROP).
- Author
-
van der Meulen, Annelot I., Neis, Evelien P. J. G., de Nijs, Ellen J. M., Coenegracht, Bénédicte J. E. G., Stoppelenburg, Arianne, van den Beuken-van Everdingen, Marieke H. J., and van der Linden, Yvette M.
- Subjects
- *
EXPERIMENTAL design , *PATIENT aftercare , *FRAIL elderly , *PROFESSIONS , *RESEARCH methodology , *PILOCARPINE , *CATASTROPHIC illness , *HEALTH literacy , *MEDICAL protocols , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *XEROSTOMIA , *COST effectiveness , *QUALITY of life , *PATIENT education , *DISEASE complications , *SYMPTOMS - Abstract
Background: Despite its prevalent and impactful nature, dry mouth remains an underexposed and undertreated symptom in patients with a life-limiting condition or frailty. The main contributing factors are a lack of awareness and knowledge amongst both healthcare professionals and patients, and a scarcity of effective, evidence-based interventions. In the DRy mOuth Project (DROP), we address these factors by investigating both a non-pharmacological and a pharmacological intervention: a nurse-led patient education program and locally applied pilocarpine. Methods: This intervention-based research project consists of two parallel studies. The non-pharmacological study is a cluster non-randomized controlled trial in 228 palliative nursing home and hospital patients, investigating the effect of structured use of guidelines and of patient education on dry mouth symptoms. This intervention, a nurse-led patient education program (the Mouth Education Program, MEP), will be compared to care as usual, the control. The pharmacological study is a double-blind placebo-controlled randomized trial that examines the effect of locally applied pilocarpine drops in 120 patients with dry mouth symptoms. Both studies use the same mixed-methods study design, in which the primary outcome is the clinical response to the intervention at 4 weeks, as measured by a dry mouth severity score (numeric rating scale from 0 to 10). Other outcomes, as measured by questionnaires over a 12-week follow-up period, include durability of the effect, impact on quality of life and, adherence and acceptability of the intervention. In addition, the feasibility and cost-effectiveness are evaluated by means of questionnaires and focus groups with healthcare professionals, and interviews with patients. Discussion: This study investigates the effectiveness and feasibility of two interventions for dry mouth symptoms in patients with life-limiting conditions or frailty. Due to the large-scale and mixed-method nature of the study, this study will also improve our understanding of dry mouth and its relating factors and of the patients' and healthcare professionals' experiences with symptoms, care and guidelines of dry mouth, including any perceived barriers and facilitators. Trial registration: NCT05964959 & NCT05506137. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. A randomized controlled trial of supervised remotely-delivered attention bias modification for posttraumatic stress disorder.
- Author
-
Alon, Yaron, Azriel, Omer, Pine, Daniel S., and Bar-Haim, Yair
- Subjects
- *
TREATMENT of post-traumatic stress disorder , *MEDICAL consultation , *RESEARCH methodology , *MEDICAL care , *INTERVIEWING , *RANDOMIZED controlled trials , *T-test (Statistics) , *RESEARCH funding , *BLIND experiment , *DESCRIPTIVE statistics , *QUESTIONNAIRES , *CHI-squared test , *DATA analysis software , *ATTENTIONAL bias , *TELEMEDICINE - Abstract
Background: Many individuals with posttraumatic stress disorder (PTSD) have limited access to first-line treatments, warranting the development of remotely-delivered treatments. Attention bias modification (ABM), targeting perturbed threat-related attentional patterns, shows promise when delivered in-person. However, previous studies found ABM to be ineffective when delivered remotely. Randomized clinical trials usually applied two variations of ABM: ABM away from threat or attention control training (ACT) balancing attention between threat-related and neutral stimuli. We tested remotely-delivered ACT/ABM with tighter supervision and video-based interactions that resemble in-clinic protocols. We expected to replicate the results of in-clinic trials, in which ACT outperformed ABM for PTSD. Methods: In this double-blinded, parallel-group randomized controlled trial, 60 patients diagnosed with PTSD were randomized (ABM n = 30; ACT n = 30). Patients performed eight bi-weekly remotely-delivered supervised ABM/ACT sessions. Symptoms were assessed pre- and post-treatment with Clinician-Administered PTSD Scale 5 (CAPS-5) severity score and PTSD diagnosis as the primary outcomes. Current depressive episode, current anxiety-related comorbidity, and time elapsed since the trauma were examined as potential moderators of treatment outcome. Results: Significant decrease in CAPS-5 severity scores and PTSD diagnosis was observed following both ACT and ABM with no between-group difference. Patients without depression or whose trauma occurred more recently had greater symptom reduction in the ACT than the ABM group. Conclusions: Contrary to our expectation, symptoms decreased similarly following ACT and ABM. Moderator analyses suggest advantage for ACT in non-depressed patients and patients whose trauma occurred more recently. Further refinements in remotely-delivered ABM/ACT may be needed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Comparison of an online versus conventional multidisciplinary collaborative weight loss programme in type 2 diabetes mellitus: A randomized controlled trial.
- Author
-
Han, Yun, Ye, Xinhua, Li, Xiaona, Yang, Ping, Wu, Yan, Chen, Liye, Wu, Haili, and He, Wenxia
- Subjects
- *
GLYCOSYLATED hemoglobin , *DIET in disease , *BODY composition , *EVALUATION of human services programs , *ANALYSIS of variance , *INTERNET , *BLOOD sugar monitoring , *FOOD consumption , *RESEARCH methodology , *MULTIVARIATE analysis , *MEDICAL care , *FOOT care , *TYPE 2 diabetes , *RANDOMIZED controlled trials , *COMPARATIVE studies , *DIET therapy , *CRONBACH'S alpha , *HEALTH care teams , *INTERPROFESSIONAL relations , *WEIGHT loss , *RESEARCH funding , *QUALITY of life , *DESCRIPTIVE statistics , *SCALE analysis (Psychology) , *CHI-squared test , *DATA analysis software , *BODY mass index , *HEALTH promotion , *HEALTH self-care - Abstract
Aim: The aim of this study was to examine the effect of an online multidisciplinary weight loss management programme. Methods: Between July 2016 and July 2017 this randomized controlled trial recruited patients in Nanjing, China who were living with type 2 diabetes mellitus and who were obese or overweight and randomized them to online versus conventional groups. All participants were managed by a multidisciplinary team. The experimental group was managed using the Why Wait WeChat Platform for Weight Reduction Management. Results: There were 55 and 52 participants in the online and conventional groups, respectively. The decreases in fasting blood glucose (−4.26 vs. −2.99 mmol/L), 2‐h postprandial blood glucose (−4.48 vs. −2.68 mmol/L) and glycated haemoglobin (−22.11 vs. −6.21 mmol/mol) were more pronounced in the online compared to conventional group (all P < 0.05). After the intervention, self‐management ability parameters, including diet control, foot care and total score, were improved in the online group compared with the conventional group, as well as all indexes of quality of life (all P < 0.05). Conclusion: The online multidisciplinary weight loss management programme improved blood glucose in obese or overweight patients living with type 2 diabetes mellitus. Self‐management ability parameters (including diet control, foot care and total score) and quality of life were improved in the online group compared with the conventional group. Summary statement: What is already known about this topic?: Multidisciplinary approaches have been introduced into weight loss management models for patients with type 2 diabetes mellitus and obese or overweight in outpatient clinics of third‐level hospitals, but their effects have not been clearly described. What this paper adds?: The online multidisciplinary weight loss management programme improved blood glucose in obese or overweight patients living with type 2 diabetes mellitus.Self‐management ability parameters (including diet control, foot care and total score) and quality of life were improved in the online group compared with the conventional group. The implications of this paper: This is the first trial of an online programme in the management of type 2 diabetes mellitus in China.Trial findings might have international applicability in the management of type 2 diabetes mellitus and could lead to improvement of prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Expectant management versus IUI in unexplained subfertility and a poor pregnancy prognosis (EXIUI study): a randomized controlled trial.
- Author
-
Wessel, J A, Mochtar, M H, Besselink, D E, Betjes, H, Bruin, J P de, Cantineau, A E P, Groenewoud, E R, Hooker, A B, Lambalk, C B, Kwee, J, Kaaijk, E M, Louwé, L A, Maas, J W M, Mol, B W J, Rumste, M M E van, Traas, M A F, Goddijn, M, Wely, M van, Mol, F, and de Bruin, J P
- Subjects
- *
INFERTILITY treatment , *EVALUATION research , *RESEARCH funding , *HUMAN artificial insemination , *EVALUATION of medical care , *RANDOMIZED controlled trials , *BIRTH rate , *RESEARCH , *RESEARCH methodology , *SOCIAL networks , *PROGNOSIS , *COMPARATIVE studies , *PSYCHOLOGICAL tests , *INDUCED ovulation - Abstract
Study Question: For couples with unexplained subfertility and a poor prognosis for natural conception, is 6 months expectant management (EM) inferior to IUI with ovarian stimulation (IUI-OS), in terms of live births?Summary Answer: In couples with unexplained subfertility and a poor prognosis for natural conception, 6 months of EM is inferior compared to IUI-OS in terms of live births.What Is Known Already: Couples with unexplained subfertility and a poor prognosis are often treated with IUI-OS. In couples with unexplained subfertility and a relatively good prognosis for natural conception (>30% in 12 months), IUI-OS does not increase the live birth rate as compared to 6 months of EM. However, in couples with a poor prognosis for natural conception (<30% in 12 months), the effectiveness of IUI-OS is uncertain.Study Design, Size, Duration: We performed a non-inferiority multicentre randomized controlled trial within the infrastructure of the Dutch Consortium for Healthcare Evaluation and Research in Obstetrics and Gynaecology. We intended to include 1091 couples within 3 years. The couples were allocated in a 1:1 ratio to 6 months EM or 6 months IUI-OS with either clomiphene citrate or gonadotrophins.Participants/materials, Setting, Methods: We studied heterosexual couples with unexplained subfertility and a poor prognosis for natural conception (<30% in 12 months). The primary outcome was ongoing pregnancy leading to a live birth. Non-inferiority would be shown if the lower limit of the one-sided 90% risk difference (RD) CI was less than minus 7% compared to an expected live birth rate of 30% following IUI-OS. We calculated RD, relative risks (RRs) with 90% CI and a corresponding hazard rate for live birth over time based on intention-to-treat and per-protocol (PP) analysis.Main Results and the Role Of Chance: Between October 2016 and September 2020, we allocated 92 couples to EM and 86 to IUI-OS. The trial was halted pre-maturely owing to slow inclusion. Mean female age was 34 years, median duration of subfertility was 21 months. Couples allocated to EM had a lower live birth rate than couples allocated to IUI-OS (12/92 (13%) in the EM group versus 28/86 (33%) in the IUI-OS group; RR 0.40 90% CI 0.24 to 0.67). This corresponds to an absolute RD of minus 20%; 90% CI: -30% to -9%. The hazard ratio for live birth over time was 0.36 (95% CI 0.18 to 0.70). In the PP analysis, live births rates were 8 of 70 women (11%) in the EM group versus 26 of 73 women (36%) in the IUI-OS group (RR 0.32, 90% CI 0.18 to 0.59; RD -24%, 90% CI -36% to -13%) in line with inferiority of EM.Limitations, Reasons For Caution: Our trial did not reach the planned sample size, therefore the results are limited by the number of participants.Wider Implications Of the Findings: This study confirms the results of a previous trial that in couples with unexplained subfertility and a poor prognosis for natural conception, EM is inferior to IUI-OS.Study Funding/competing Interest(s): The trial was supported by a grant of the SEENEZ healthcare initiative. The subsidizing parties were The Dutch Organisation for Health Research and Development (ZonMW 837004023, www.zonmw.nl) and the umbrella organization of 10 health insurers in The Netherlands. E.R.G. receives personal fees from Titus Health care outside the submitted work. M.G. declares unrestricted research and educational grants from Guerbet, Merck and Ferring not related to the presented work, paid to their institution VU medical centre. A.B.H. reports receiving travel and speakers fees from Nordic Pharma and Merck and he is member of the Nordic Pharma ANGEL group and of the Safety Monitoring Board of Womed. C.B.L. reports speakers fee from Inmed and Yingming, and his department receives research grants from Ferring, Merck and Guerbet paid to VU medical centre. B.W.J.M. is supported by a NHMRC Investigator grant (GNT1176437) and reports consultancy for ObsEva and Merck. M.v.W. received a grant from the Netherlands Organisation for Health Research and Development ZonMW (80-8520098-91072). F.M. received two grants from the Netherlands Organisation for Health Research and Development ZonMW (NTR 5599 and NTR 6590). The other authors report no competing interest.Trial Registration Number: Dutch Trial register NL5455 (NTR5599).Trial Registration Date: 18 December 2015.Date Of First Patient’s Enrolment: 26 January 2017. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial.
- Author
-
Pillai, Kanchana Soman, Bhat, Priyanka, Srivastava, Achal Kumar, Rajan, Roopa, Radhakrishnan, Divya M., Elavarasi, Arunmozhimaran, Srivastava, MV Padma, Singh, Mamta Bhushan, Vishnu, V.Y., Prasad, Kameshwar, Pandit, Awadh Kishor, and Goyal, Vinay
- Subjects
- *
DRUG therapy for Parkinson's disease , *EVALUATION research , *BLIND experiment , *PARKINSON'S disease , *TREATMENT effectiveness , *TREMOR , *RANDOMIZED controlled trials , *ESSENTIAL tremor , *RESEARCH , *RESEARCH methodology , *COMPARATIVE studies , *DISEASE complications - Abstract
Introduction: and objective: Tremor is a disabling symptom of PD that usually responds poorly to available standard pharmacological agents. This study aimed to assess the effect of Zonisamide 25 mg on tremor in tremor-dominant PD patients as compared to placebo.Methods: This was a randomized, placebo-controlled, double-blind study. Parkinson's disease patients were allocated either to the intervention group (standard treatment along with Zonisamide 25 mg add-on) or the placebo group (standard treatment along with placebo). Baseline Unified Parkinson's Disease Rating Scale (UPDRS) and Tremor Research Group Essential Tremor Rating Scale (TETRAS) scores, as well as accelerometric tremor analysis were done and follow-up assessments of the same were done after 12 weeks of intervention. Percentage change from baseline in the UPDRS tremor score was the primary outcome whereas percentage change from baseline of total UPDRS score, UPDRS rigidity and bradykinesia scores, TETRAS score, and accelerometric tremor analysis values were the secondary outcomes.Results: There was no significant difference in the percentage change from baseline UPDRS tremor scores between the two groups (placebo: 8.33 [-19.89-23.86] vs drug: 26.14 [-35.58 to -16.07], p-value: 0.164, CI: 0.157-0.171). Best-case analysis for missing values showed a significant improvement in the drug group, compared to the placebo group (p-value: < 0.001, CI: <0.001 - <0.001).Conclusion: Zonisamide at a dose of 25 mg per day did not improve tremor in tremor-dominant PD patients, however, a positive trend was seen as compared to Placebo in the UPDRS tremor score. Larger studies are required to confirm this finding. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Steroid treatment as anti-inflammatory and neuroprotective agent following out-of-hospital cardiac arrest: a randomized clinical trial.
- Author
-
Obling, Laust Emil Roelsgaard, Beske, Rasmus Paulin, Wiberg, Sebastian, Folke, Fredrik, Moeller, Jacob Eifer, Kjaergaard, Jesper, and Hassager, Christian
- Subjects
- *
CARDIAC arrest , *ANTI-inflammatory agents , *CLINICAL trials , *NEUROPROTECTIVE agents , *RETURN of spontaneous circulation , *GLUCOCORTICOIDS , *STEROID drugs , *EVALUATION research , *RESEARCH funding , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *GLASGOW Coma Scale , *RESEARCH , *RESEARCH methodology , *INFLAMMATION , *METHYLPREDNISOLONE , *COMPARATIVE studies - Abstract
Background: Patients resuscitated from out-of-hospital cardiac arrest (OHCA) have a high morbidity and mortality risk and often develop post-cardiac arrest syndrome (PCAS) involving systemic inflammation. The severity of the inflammatory response is associated with adverse outcome, with anoxic irreversible brain injury as the leading cause of death following resuscitated OHCA. The study aimed to investigate the anti-inflammatory and neuroprotective effect of pre-hospital administration of a high-dose glucocorticoid following OHCA.Methods: The study is an investigator-initiated, randomized, multicenter, single-blinded, placebo-controlled, clinical trial. Inclusion will continue until one hundred twenty unconscious OHCA patients surviving a minimum of 72 h are randomized. Intervention is a 1:1 randomization to an infusion of methylprednisolone 250 mg following a minimum of 5 min of sustained return of spontaneous circulation in the pre-hospital setting. Methylprednisolone will be given as a bolus infusion of 1 × 250 mg (1 × 4 mL) over a period of 5 min. Patients allocated to placebo will receive 4 mL of isotonic saline (NaCl 0.9%). Main eligibility criteria are OHCA of presumed cardiac cause, age ≥ 18 years, Glasgow Coma Scale ≤ 8, and sustained ROSC for at least 5 min. Co-primary endpoint: Reduction of interleukin-6 and neuron-specific-enolase. Secondary endpoints: Markers of inflammation, brain, cardiac, kidney and liver damage, hemodynamic and hemostatic function, safety, neurological function at follow-up, and mortality. A research biobank is set up with blood samples taken daily during the first 72 h from hospitalization to evaluate primary and secondary endpoints.Discussion: We hypothesize that early anti-inflammatory steroid treatment in the pre-hospital setting can mitigate the progression of PCAS following resuscitated OHCA. Primary endpoints will be assessed through analyses of biomarkers for inflammation and neurological damage taken during the first 72 h of admission.Trial Registration: EudraCT number: 2020-000855-11 ; submitted March 30, 2020 ClinicalTrials.gov Identifier: NCT04624776; submitted October 12, 2020, first posted November 10, 2020. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Improved Relationship Quality, Equitable Gender Attitudes, and Reduced Alcohol Abuse as Key Mechanisms to Reduce Intimate Partner Violence in the Bandebereho Couples' Randomized Trial in Rwanda.
- Author
-
Levtov, Ruti G., Doyle, Kate, Bingenheimer, Jeffrey B., Lahiri, Shaon, Kazimbaya, Shamsi, Karamage, Emmanuel, Sayinzoga, Felix, Mutoni, Merab, Rubayita, Claude Hodari, and Barker, Gary
- Subjects
- *
PREVENTION of alcoholism , *RESEARCH , *FERRANS & Powers Quality of Life Index , *RESEARCH methodology , *EVALUATION research , *GENDER identity , *COMPARATIVE studies , *RANDOMIZED controlled trials , *ALCOHOL drinking , *IMPACT of Event Scale , *QUESTIONNAIRES , *RESEARCH funding - Abstract
Over the past decade, there has been rapid growth in the evidence for programs to prevent or reduce intimate partner violence (IPV)-the most common form of men's violence against women. IPV interventions targeting heterosexual couples have shown significant impact. However, our understanding of how these interventions achieve their impacts on violence-the mechanisms through which change occurs-remains limited. Using data from two follow-up rounds of a randomized controlled trial of the Bandebereho intervention in Rwanda, we constructed conceptually driven structural equation models to represent the processes by which hypothesized mediating variables linked treatment assignment to IPV. We found significant differences in the expected direction between the intervention and control participants on all mediating variables, including men's alcohol use, communication frequency, emotional closeness, frequency of quarreling, and men's attitudes related to gender and violence. Several mechanisms-more positive couple dynamics including emotional closeness and communication frequency; men's gender-equitable attitudes; men's alcohol use-accounted for the largest proportions of the effect of assignment to the Bandebereho intervention on IPV. Overall, our findings highlight that no one particular component is driving the reductions in violence; instead, the multiple components and pathways account for the intervention's effects, suggesting that the holistic nature of the intervention may be integral to its positive impact. The Bandebereho trial from which data was used in this analysis was registered on ClinicalTrials.gov prior to completion ( NCT02694627 ). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Effects of Computer-Assisted Social Skills Training in Children With Disruptive Behavior Disorders: A Randomized Controlled Trial.
- Author
-
Goertz-Dorten, Anja, Dose, Christina, Hofmann, Leonie, Katzmann, Josepha, Groth, Manuela, Detering, Kerstin, Hellmann, Anne, Stadler, Laura, Braun, Barbara, Hellmich, Martin, and Doepfner, Manfred
- Subjects
- *
BEHAVIOR disorders in children , *CONDUCT disorders in children , *SOCIAL skills education , *OPPOSITIONAL defiant disorder in children , *RANDOMIZED controlled trials , *CHILD psychology , *RESEARCH , *RESEARCH methodology , *EVALUATION research , *ATTENTION-deficit hyperactivity disorder , *COMPARATIVE studies , *CHILD psychopathology , *QUALITY of life , *SOCIAL skills - Abstract
Objective: Computer-assisted child-focused interventions are expected to improve efficiency and personalization of therapist-led treatments for children and adolescents. However, therapist-led, outpatient interventions using computer assistance are lacking for children with oppositional defiant disorder (ODD) or conduct disorder (CD). The present randomized controlled trial examined the efficacy of individualized computer-assisted social skills training for children with aggressive behavior compared to a resource activation intervention.Method: A total of 100 children aged 6-12 years with a diagnosis of ODD/CD and peer-related aggression were randomly (1:1) assigned to either individually delivered computer-assisted social skills training (ScouT) or an individually delivered supportive resource activation treatment (STARK). The primary outcome was parent-rated peer-related aggression, assessed with the respective scale of the Questionnaire for Aggressive Behavior of Children (FAVK) and measured at pre-assessment and after the 16-week intervention (post-assessment). Further parent-, self-, teacher- and/or clinician-rated outcomes included ODD and CD symptoms, a wide range of behavioral and emotional symptoms, callous-unemotional traits, functional impairment, and quality of life.Results: After correcting for multiple testing, analyses of covariance comparing the efficacy of ScouT to the efficacy of STARK yielded small to moderate treatment effects in favor of the ScouT condition regarding parent-rated peer-related aggression (primary outcome; d = -0.64, 95% CI = -1.05, -0.24), parent-rated callous and uncaring traits, and parent-rated quality of life. However, the analyses did not reveal any significant effects for self- or teacher-rated peer-related aggression assessed with the respective scale of the FAVK (self-report: d = -0.21, 95% CI = -0.69, 0.29; teacher rating: d = -0.17, 95% CI = -0.56, 0.22). Moreover, after controlling for multiple comparisons, no significant effects emerged for the following: parent-, self-, and teacher-rated adult-related aggression; parent-, self-, teacher-, and clinician-rated ODD and CD symptoms; parent-, self-, and teacher-rated emotional and behavioral symptoms; and parent-rated functional impairment.Conclusion: According to parent ratings, school-age children with disruptive behavior disorders and peer-related aggression seem to benefit more from individualized, computer-assisted social skills training than from resource activation treatment. However, this conclusion is limited by the missing effects on the clinician-, self-, and teacher-rated measures.Clinical Trial Registration Information: Treatment of Children With Peer Related Aggressive Behavior (ScouT); https://clinicaltrials.gov/; NCT02143427. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
11. Cognitive-Behavioral Versus Supportive Psychotherapy for Intermittent Explosive Disorder: A Randomized Controlled Trial.
- Author
-
McCloskey, Michael S., Chen, Eunice Y., Olino, Thomas M., and Coccaro, Emil F.
- Subjects
- *
PSYCHOTHERAPY , *RANDOMIZED controlled trials , *BECK Depression Inventory , *CLINICAL trials , *AGGRESSION (Psychology) , *PSYCHODYNAMIC psychotherapy , *RESEARCH , *RESEARCH methodology , *COGNITION , *EVALUATION research , *COMPARATIVE studies , *PSYCHOLOGICAL tests , *RESEARCH funding , *QUESTIONNAIRES , *ANGER , *PSYCHOSOCIAL factors - Abstract
Few clinical trials have evaluated the efficacy of psychotherapy for Intermittent Explosive Disorder (IED). The present study tested the efficacy of a cognitive behavioral intervention (versus supportive psychotherapy) among adults with IED. In this randomized clinical trial, 44 participants with IED (22 men and 22 women) aged 20-55 years completed twelve 50-minute individual sessions of either a multi-component cognitive behavioral intervention for IED (n = 19) or a time equated supportive psychotherapy (n = 25). At baseline, posttreatment, and 3-month follow-up, all participants received the Overt Aggression Scale-Modified, which was conducted by an interviewer who was blind to the participant's study condition. During these visits, participants also completed self-report measures of relational aggression (Self-Report of Relational Aggression and Social Behavior), anger (State-Trait Anger Expression Inventory-2), cognitive biases (e.g., Social Information Processing Questionnaire Attribution and Emotional Response Questionnaire), and associated symptoms (e.g., Beck Depression Inventory). Primary study outcomes were aggressive behavior and anger. Though participants in both treatments tended to improve over time, the cognitive behavioral intervention was superior to supportive psychotherapy in decreasing aggressive behavior and relational aggression. These findings support the efficacy of a multicomponent cognitive behavioral intervention in treating aggression in IED. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Mechanistic insights into the health benefits of fish-oil supplementation against fine particulate matter air pollution: a randomized controlled trial.
- Author
-
Zhou, Lu, Jiang, Yixuan, Lin, Zhijing, Chen, Renjie, Niu, Yue, and Kan, Haidong
- Subjects
- *
FISH oils , *OMEGA-6 fatty acids , *OMEGA-3 fatty acids , *PARTICULATE matter , *AIR pollution , *RANDOMIZED controlled trials , *UNSATURATED fatty acids , *DIETARY supplements , *AIR pollution prevention , *VEGETABLE oils , *EVALUATION research , *RESEARCH funding , *BLIND experiment , *RESEARCH , *RESEARCH methodology , *COMPARATIVE studies - Abstract
Background: Dietary fish-oil supplementation might attenuate the associations between fine particulate matter (PM2.5) and subclinical biomarkers. However, the molecular mechanisms remain to be elucidated. This study aimed to explore the molecular mechanisms of fish-oil supplementation against the PM2.5-induced health effects.Methods: We conducted a randomized, double-blinded, and placebo-controlled trial among healthy college students in Shanghai, China, from September 2017 to January 2018. A total of 70 participants from the Fenglin campus of Fudan University were included. We randomly assigned participants to either supplementation of 2.5-gram fish oil (n = 35) or sunflower-seed oil (placebo) (n = 35) per day and conducted four rounds of health measurements in the last two months of the trial. As a post hoc exploratory study, the present untargeted metabolomics analysis used remaining blood samples collected in the previous trial and applied a Metabolome-Wide Association Study framework to compare the effects of PM2.5 on the metabolic profile between the sunflower-seed oil and fish oil groups.Results: A total of 65 participants completed the trial (34 of the fish oil group and 31 of the sunflower-seed oil group). On average, ambient PM2.5 concentration on the day of health measurements was 34.9 µg/m3 in the sunflower-seed oil group and 34.5 µg/m3 in the fish oil group, respectively. A total of 3833 metabolites were significantly associated with PM2.5 in the sunflower-seed oil group and 1757 in the fish oil group. Of these, 1752 metabolites showed significant between-group differences. The identified differential metabolites included arachidonic acid derivatives, omega-3 fatty acids, omega-6 fatty acids, and omega-9 fatty acids that were related to unsaturated fatty acid metabolism, which plays a role in the inflammatory responses.Conclusion: This trial suggests fish-oil supplementation could mitigate the PM2.5-induced inflammatory responses via modulating fatty acid metabolism, providing biological plausibility for the health benefits of fish-oil supplementation against PM2.5 exposure.Trial Registration: This study is registered at ClinicalTrails.gov (NCT03255187). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
13. Interdisciplinary collaboration across secondary and primary care to improve medication safety in the elderly (The IMMENSE study) - a randomized controlled trial.
- Author
-
Johansen, Jeanette Schultz, Halvorsen, Kjell H., Svendsen, Kristian, Havnes, Kjerstin, Robinson, Eirin Guldsten, Wetting, Hilde Ljones, Haustreis, Stine, Småbrekke, Lars, Kamycheva, Elena, and Garcia, Beate Hennie
- Subjects
- *
EVALUATION research , *DISCHARGE planning , *MEDICATION reconciliation , *HOSPITAL emergency services , *RANDOMIZED controlled trials , *RESEARCH , *RESEARCH methodology , *COMPARATIVE studies , *PATIENT aftercare - Abstract
Background: Suboptimal medication use contributes to a substantial proportion of hospitalizations and emergency department visits in older adults. We designed a clinical pharmacist intervention to optimize medication therapy in older hospitalized patients. Based on the integrated medicine management (IMM) model, the 5-step IMMENSE intervention comprise medication reconciliation, medication review, reconciled medication list upon discharge, patient counselling, and post discharge communication with primary care. The objective of this study was to evaluate the effects of the intervention on healthcare use and mortality.Methods: A non-blinded parallel group randomized controlled trial was conducted in two internal medicine wards at the University Hospital of North Norway. Acutely admitted patients ≥ 70 years were randomized 1:1 to intervention or standard care (control). The primary outcome was the rate of emergency medical visits (readmissions and emergency department visits) 12 months after discharge.Results: Of the 1510 patients assessed for eligibility, 662 patients were asked to participate, and 516 were enrolled. After withdrawal of consent and deaths in hospital, the modified intention-to-treat population comprised 480 patients with a mean age of 83.1 years (SD: 6.3); 244 intervention patients and 236 control patients. The number of emergency medical visits in the intervention and control group was 497 and 499, respectively, and no statistically significant difference was observed in rate of the primary outcome between the groups [adjusted incidence rate ratio of 1.02 (95% CI: 0.82-1.27)]. No statistically significant differences between groups were observed for any of the secondary outcomes, neither in subgroups, nor for the per-protocol population.Conclusions: We did not observe any statistical significant effects of the IMMENSE intervention on the rate of emergency medical visits or any other secondary outcomes after 12 months in hospitalized older adults included in this study.Trial Registration: The trial was registered in clinicaltrials.gov on 28/06/2016, before enrolment started (NCT02816086). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
14. Response heterogeneity in a randomized controlled trial of telerehabilitation interventions among adults with multiple sclerosis.
- Author
-
Plow, Matthew, Motl, Robert W, Finlayson, Marcia, and Bethoux, Francois
- Subjects
- *
RANDOMIZED controlled trials , *TELEREHABILITATION , *MULTIPLE sclerosis , *RANDOMIZED response , *CANCER fatigue , *FATIGUE (Physiology) , *RESEARCH , *RESEARCH methodology , *EVALUATION research , *COMPARATIVE studies , *EXERCISE , *QUESTIONNAIRES - Abstract
Introduction: Telerehabilitation may be effective on average but is not equally effective among all people with multiple sclerosis (MS). Thus, the purpose of this secondary analysis of a randomized controlled trial was to explore whether baseline characteristics of participants with MS influence fatigue and physical activity outcomes of three telerehabilitation interventions.Methods: Participants were randomized to contact-control intervention (CC), physical activity-only intervention (PA-only), and physical activity plus fatigue self-management intervention (FM+). The 12-week interventions were delivered over the phone. Sociodemographic (age and income), clinical (comorbidities, mental function and physical function), psychosocial (self-efficacy, outcome expectations and goal-setting), and behavioural baseline characteristics (step count and fatigue self-management behaviors) were used in a moderated regression analysis and a responder analysis to examine their influence on the Fatigue Impact Scale (FIS) and Godin Leisure-Time Exercise Questionnaire (GLTEQ) at post-test (i.e. immediately post-interventions).Results: No interactions terms were statistically significant in the moderation analysis. However, the responder analysis showed that baseline psychosocial characteristics and mental function were significantly different (p < 0.05) between responders and non-responders. Specifically, non-responders on the FIS at post-test in the PA-only intervention had significantly lower baseline scores in goal setting for engaging in fatigue self-management behaviours. Also, non-responders on the GLTEQ at post-test in the FM+ intervention had significantly worse baseline scores in mental function.Discussion: Further research is needed to understand the complex relationship among baseline characteristics, telerehabilitation and response heterogeneity. We discuss how research on examining response heterogeneity may be advanced by conducting mega-clinical trials, secondary analyses of big data, meta-analyses and employing non-traditional research designs.Trial Registration: Clinicaltrials.gov (NCT01572714). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
15. The effect of a psychoeducation program based on the rational emotional behavioral approach in individuals with multiple sclerosis diagnosis: A randomized controlled trial.
- Author
-
Şahin, Emel, Güleç Keskin, Serap, and Terzi, Murat
- Subjects
- *
MULTIPLE sclerosis , *HEALTH education , *EVALUATION of human services programs , *SAMPLE size (Statistics) , *ANALYSIS of variance , *RESEARCH methodology , *EFFECT sizes (Statistics) , *PSYCHOEDUCATION , *COGNITION , *MENTAL health , *HEALTH outcome assessment , *RANDOMIZED controlled trials , *PRE-tests & post-tests , *COMPARATIVE studies , *T-test (Statistics) , *QUESTIONNAIRES , *HYPOTHESIS , *DESCRIPTIVE statistics , *EMOTION regulation , *STATISTICAL sampling , *SOCIODEMOGRAPHIC factors , *PSYCHOLOGICAL adaptation - Abstract
Purpose: This study aimed to examine the effects of a psychoeducational program on the cognitive emotion regulation levels of individuals with multiple sclerosis (MS). Design and Method: This study followed a randomized, controlled quasi‐experimental design. A questionnaire including descriptive characteristics and disease‐related characteristics and the Cognitive Emotion Regulation Questionnaire were used in the data collection. Findings: The difference between the pretest–posttest and follow‐up test mean scores of the patients in the experimental group was significant (p < 0.05). Conclusion: The psychoeducation program based on the rational emotional behavioral approach increased the use of cognitive emotion regulation strategies in individuals with MS. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Effectiveness of an online self‐help program, expert‐patient support, and their combination for eating disorders: Results from a randomized controlled trial.
- Author
-
Rohrbach, Pieter J., Dingemans, Alexandra E., Spinhoven, Philip, Van Ginkel, Joost R., Fokkema, Marjolein, Wilderjans, Tom F., Bauer, Stephanie, and Van Furth, Eric F.
- Subjects
- *
EVALUATION of medical care , *PREVENTION of eating disorders , *STATISTICAL significance , *STATISTICS , *SOCIAL support , *EVALUATION of human services programs , *ANALYSIS of variance , *FACTORIAL experiment designs , *INTERNET , *RESEARCH methodology , *SOCIAL media , *REGRESSION analysis , *RANDOMIZED controlled trials , *CRONBACH'S alpha , *CHI-squared test , *DESCRIPTIVE statistics , *QUESTIONNAIRES , *STATISTICAL sampling , *STATISTICAL models , *LOGISTIC regression analysis , *STATISTICAL correlation , *DATA analysis , *EATING disorders , *HEALTH self-care , *PSYCHOSOCIAL factors - Abstract
Objective: Many individuals with an eating disorder do not receive appropriate care. Low‐threshold interventions could help bridge this treatment gap. The study aim was to evaluate the effectiveness of Featback, a fully automated online self‐help intervention, online expert‐patient support and their combination. Method: A randomized controlled trial with a 12‐month follow‐up period was conducted. Participants aged 16 or older with at least mild eating disorder symptoms were randomized to four conditions: (1) Featback, a fully automated online self‐help intervention, (2) chat or email support from a recovered expert patient, (3) Featback with expert‐patient support and (4) a waiting list control condition. The intervention period was 8 weeks and there was a total of six online assessments. The main outcome constituted reduction of eating disorder symptoms over time. Results: Three hundred fifty five participants, of whom 43% had never received eating disorder treatment, were randomized. The three active interventions were superior to a waitlist in reducing eating disorder symptoms (d = −0.38), with no significant difference in effectiveness between the three interventions. Participants in conditions with expert‐patient support were more satisfied with the intervention. Discussion: Internet‐based self‐help, expert‐patient support and their combination were effective in reducing eating disorder symptoms compared to a waiting list control condition. Guidance improved satisfaction with the internet intervention but not its effectiveness. Low‐threshold interventions such as Featback and expert‐patient support can reduce eating disorder symptoms and reach the large group of underserved individuals, complementing existing forms of eating disorder treatment. Public significance statement: Individuals with eating‐related problems who received (1) a fully automated internet‐based intervention, (2) chat and e‐mail support by a recovered individual or (3) their combination, experienced stronger reductions in eating disorder symptoms than those who received (4) usual care. Such brief and easy‐access interventions play an important role in reaching individuals who are currently not reached by other forms of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Vitamin D Supplementation and Antibiotic Use in Older Australian Adults: An Analysis of Data From the D-Health Trial.
- Author
-
Pham, Hai, Waterhouse, Mary, Baxter, Catherine, Romero, Briony Duarte, McLeod, Donald S A, Armstrong, Bruce K, Ebeling, Peter R, English, Dallas R, Hartel, Gunter, Kimlin, Michael G, O'Connell, Rachel L, Pols, Jolieke C van der, Venn, Alison J, Webb, Penelope M, Whiteman, David C, Neale, Rachel E, Duarte Romero, Briony, and van der Pols, Jolieke C
- Subjects
- *
DIETARY supplements , *VITAMIN D , *AUSTRALIANS , *OLDER people , *CLINICAL trial registries , *ANTIBIOTICS , *VITAMIN therapy , *THERAPEUTIC use of vitamin D , *RESEARCH , *RESEARCH methodology , *CHOLECALCIFEROL , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *RESEARCH funding - Abstract
Background: Vitamin D supplementation may reduce the risk or severity of infection, but this has been investigated in few large population-based trials. We analyzed data from the D-Health Trial, using prescription of antibiotics as a surrogate for infection.Methods: The D-Health Trial is a randomized, double-blind, placebo-controlled trial in which 21 315 Australians aged 60-84 years were randomized to 60 000 IU of supplementary vitamin D3 or placebo monthly for 5 years. For this analysis, the primary outcome was the number of antibiotic prescription episodes; secondary outcomes were total number of prescriptions, repeat prescription episodes, and antibiotics for urinary tract infection. We estimated incidence rate ratios (IRRs) using negative binomial regression, and odds ratios using logistic regression.Results: Vitamin D supplementation slightly reduced the number of prescription episodes (IRR, 0.98; 95% confidence interval [CI], .95-1.01), total prescriptions (IRR, 0.97; 95% CI, .93-1.00), and repeat prescription episodes (IRR, 0.96; 95% CI, .93-1.00). There was stronger evidence of benefit in people predicted to have insufficient vitamin D at baseline (prescription episodes IRR, 0.93; 95% CI, .87-.99).Conclusions: Vitamin D may reduce the number of antibiotic prescriptions, particularly in people with low vitamin D status. This supports the hypothesis that vitamin D has a clinically relevant effect on the immune system.Clinical Trials Registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000743763. https://www.anzctr.org.au/. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
18. Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease.
- Author
-
Vermeulen, Emma A., Eelderink, Coby, Hoekstra, Tiny, van Ballegooijen, Adriana J., Raijmakers, Pieter, Beulens, Joline W., de Borst, Martin H., and Vervloet, Marc G.
- Subjects
- *
CHRONIC kidney failure , *RESEARCH , *CARDIOVASCULAR system physiology , *INFLAMMATION , *RESEARCH methodology , *ARTHRITIS Impact Measurement Scales , *CITRATES , *EVALUATION research , *ORGANOMETALLIC compounds , *DIETARY supplements , *COMPARATIVE studies , *RANDOMIZED controlled trials , *CALCINOSIS , *MAGNESIUM , *RESEARCH funding , *VASCULAR diseases , *PHOSPHATES , *DISEASE complications ,CHRONIC kidney failure complications - Abstract
Background: Arterial stiffness and calcification propensity are associated with high cardiovascular risk and increased mortality in chronic kidney disease (CKD). Both magnesium and phosphate are recognized as modulators of vascular calcification and chronic inflammation, both features of CKD that contribute to arterial stiffness. In this paper, we outline the rationale and design of a randomized controlled trial (RCT) investigating whether 24 weeks of oral magnesium supplementation with or without additional phosphate-binding therapy can improve arterial stiffness and calcification propensity in patients with stage 3-4 CKD.Methods: In this multi-center, placebo-controlled RCT, a total of 180 participants with an estimated glomerular filtration rate of 15 to 50 ml/min/1.73 m2 without phosphate binder therapy will be recruited. During the 24 weeks intervention, participants will be randomized to one of four intervention groups to receive either magnesium citrate (350 mg elemental magnesium/day) or placebo, with or without the addition of the phosphate binder sucroferric oxyhydroxide (1000 mg/day). Primary outcome of the study is the change of arterial stiffness measured by the carotid-femoral pulse wave velocity over 24 weeks. Secondary outcomes include markers of calcification and inflammation, among others calcification propensity (T50) and high-sensitivity C-reactive protein. As explorative endpoints, repeated 18F-FDG and 18F-NaF PET-scans will be performed in a subset of participants (n = 40). Measurements of primary and secondary endpoints are performed at baseline, 12 and 24 weeks.Discussion: The combined intervention of magnesium citrate supplementation and phosphate-lowering therapy with sucroferric oxyhydroxide, in stage 3-4 CKD patients without overt hyperphosphatemia, aims to modulate the complex and deregulated mineral metabolism leading to vascular calcification and arterial stiffness and to establish to what extent this is mediated by T50 changes. The results of this combined intervention may contribute to future early interventions for CKD patients to reduce the risk of CVD and mortality.Trial Registration: Netherlands Trial Register, NL8252 (registered December 2019), EU clinical Trial Register 2019-001306-23 (registered November 2019). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
19. The effects of aerobic exercise on body composition in overweight and obese patients with gout: a randomized, open-labeled, controlled trial.
- Author
-
Jia, Ertao, Zhu, Haiqiong, Geng, Hongling, Liu, Ruilin, Wo, Xueqian, Zeng, Yaochi, Ma, Wukai, Yao, Xueming, Zhan, Zhiying, and Zhang, Jianyong
- Subjects
- *
OBESITY complications , *GOUT treatment , *OBESITY treatment , *GOUT diagnosis , *OBESITY , *BODY composition , *HDL cholesterol , *RESEARCH , *RESEARCH methodology , *ARTHRITIS Impact Measurement Scales , *SELF-evaluation , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *EXERCISE , *RESEARCH funding , *URIC acid , *EXERCISE therapy , *HEALTH self-care - Abstract
Background: Overweight and obesity are typical risk factors for the increased prevalence and incidence of gout. The existing guidelines unequivocally indicated that exercise is highly advantageous for patients with gout. Nevertheless, there is still a lack of specific guidance and clinical evidence. The effects of exercise on improving gout, and the optimal frequency, timing, and types of exercise have not been fully clarified. The present trial aims to determine the effects of a specific aerobic exercise program on body composition in overweight and obese patients with gout.Methods: In this randomized, open-labeled, controlled trial, a total of 60 overweight and obese patients with gout [body mass index (BMI) ≥ 24 kg/m2; age,18-55 years old] are equally randomized (1:1) into two groups (n = 30): moderate-intensity aerobic exercise group (MIAEG), heart rate reserve (HRR) = [(HRmax-HRrest) × 60% intensity] + HRrest, and control group (CG). The moderate-intensity aerobic exercise training program will be conducted for 30-40 min/session and 3 days/week for 12 weeks. Participants in the CG will be asked to avoid making changes in their exercise habits. There will be no limitation in the type of exercise. The primary outcome is the number of patients whose body fat is reduced after 12 weeks. The secondary outcomes include the changes in BMI, waist-to-hip ratio (WHR), insulin resistance index (IRI), serum uric acid (sUA), serum creatinine (SCr), estimated glomerular filtration rate (eGFR), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), hepatic steatosis, and adverse effects after 12 weeks. One-way analysis of variance (ANOVA) will be used to compare the mean values of normally distributed variables between MIAEG and GC.Discussion: The effect and optimal frequency of exercise for improving the status of overweight and obese patients with gout have not yet been determined. We design a 12-week randomized controlled trial and evaluate the effects of individualized aerobic exercise program on patients with gout. The results may assist such patients with a personalized scientific exercise program based on the disease status and motor abilities, so that patients are prone to exercise under the condition of low risk and achieve the greatest benefits.Trial Registration: ChiCTR2200062153. Registered on July 25, 2022, with ChiCTR. http://www.chictr.org.cn/. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
20. Routine Pressure Wire Assessment Versus Conventional Angiography in the Management of Patients With Coronary Artery Disease: The RIPCORD 2 Trial.
- Author
-
Stables, Rodney H., Mullen, Liam J., Elguindy, Mostafa, Nicholas, Zoe, Aboul-Enien, Yousra H., Kemp, Ian, O'Kane, Peter, Hobson, Alex, Johnson, Thomas W., Khan, Sohail Q., Wheatcroft, Stephen B., Garg, Scot, Zaman, Azfar G., Mamas, Mamas A., Nolan, James, Jadhav, Sachin, Berry, Colin, Watkins, Stuart, Hildick-Smith, David, and Gunn, Julian
- Subjects
- *
CORONARY artery disease , *ANGIOGRAPHY , *CORONARY angiography , *VISUAL analog scale , *MYOCARDIAL infarction , *RESEARCH , *CORONARY artery stenosis , *RESEARCH methodology , *MEDICAL care , *EVALUATION research , *CARDIOVASCULAR system , *CORONARY circulation , *NATIONAL health services , *TREATMENT effectiveness , *COMPARATIVE studies , *RANDOMIZED controlled trials , *QUALITY of life - Abstract
Background: Measurement of fractional flow reserve (FFR) has an established role in guiding percutaneous coronary intervention. We tested the hypothesis that, at the stage of diagnostic invasive coronary angiography, systematic FFR-guided assessment of coronary artery disease would be superior, in terms of resource use and quality of life, to assessment by angiography alone.Methods: We performed an open-label, randomized, controlled trial in 17 UK centers, recruiting 1100 patients undergoing invasive coronary angiography for the investigation of stable angina or non-ST-segment-elevation myocardial infarction. Patients were randomized to either angiography alone (angiography) or angiography with systematic pressure wire assessment of all epicardial vessels >2.25 mm in diameter (angiography+FFR). The coprimary outcomes assessed at 1 year were National Health Service hospital costs and quality of life. Prespecified secondary outcomes included clinical events.Results: In the angiography+FFR arm, the median number of vessels examined was 4 (interquartile range, 3-5). The median hospital costs were similar: angiography, £4136 (interquartile range, £2613-£7015); and angiography+FFR, £4510 (£2721-£7415; P=0.137). There was no difference in median quality of life using the visual analog scale of the EuroQol EQ-5D-5L: angiography, 75 (interquartile range, 60-87); and angiography+FFR, 75 (interquartile range, 60-90; P=0.88). The number of clinical events was as follows: deaths, 5 versus 8; strokes, 3 versus 4; myocardial infarctions, 23 versus 22; and unplanned revascularizations, 26 versus 33, with a composite hierarchical event rate of 8.7% (48 of 552) for angiography versus 9.5% (52 of 548) for angiography+FFR (P=0.64).Conclusions: A strategy of systematic FFR assessment compared with angiography alone did not result in a significant reduction in cost or improvement in quality of life.Registration: URL: https://www.Clinicaltrials: gov; Unique identifier: NCT01070771. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
21. Preoperative smoking cessation program in patients undergoing intermediate to high-risk surgery: a randomized, single-blinded, controlled, superiority trial.
- Author
-
Fankhauser, Christian D., Affentranger, Andres, Cortonesi, Beatrice, Jeker, Urs, Gass, Markus, Minervini, Fabrizio, Jung, Georg, Christmann, Corina, Brambs, Christine, Puhan, Milo A., and Held, Ulrike
- Subjects
- *
SMOKING cessation , *EVALUATION research , *NICOTINE , *MEDICAL care , *SMOKING , *RANDOMIZED controlled trials , *FERRANS & Powers Quality of Life Index , *QUALITY of life , *RESEARCH , *RESEARCH methodology , *COMPARATIVE studies , *IMPACT of Event Scale - Abstract
Background: At present, effectively implementing smoking cessation programs in the health care system constitutes a major challenge. A unique opportunity to initiate smoking cessation focuses on smokers scheduled for surgery. These patients are not only highly motivated to quit smoking but also likely to benefit from a reduction in postoperative complications which may translate into a decrease of costs. Nevertheless, surgical patients are not routinely informed about the benefits of preoperative smoking cessation. Potential reasons for this missed opportunity may be the lack of time and training of surgeons and anaesthesiologists. We therefore aim to analyse the impact of a preoperative high-intensity smoking cessation intervention on surgical complications up to a 90-day postoperative period in patients of various surgical disciplines. The hypothesis is that a preoperative smoking cessation program improves outcomes in smokers undergoing intermediate to high-risk surgery.Methods: The present study is a single-centre, randomized trial with two parallel groups of smokers scheduled for surgery comparing surgery alone and surgery with preoperative smoking cessation. We plan to randomize 251 patients. The primary objective is to compare complications between patients with an institutional multifaceted smoking cessation intervention starting 4 weeks before surgery compared to patients in the advice-only group (control group) within a 90-day postoperative period. The primary endpoint is the Comprehensive Complication Index (CCI®) within 90 days of surgery. Secondary outcomes include the length of hospital stay, cost of care, quality of life, smoking abstinence, and reduction in nicotine consumption.Discussion: The hypothesis is that a preoperative smoking cessation program improves outcomes in smokers undergoing surgery.Trial Registration: BASEC #2021-02004; ClinicalTrials.gov: NCT05192837 . Registered on January 14, 2022. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
22. Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: a prospective, multicenter, randomized, double-blind, controlled clinical study.
- Author
-
Ning, Houxu, Zhou, Hao, Ren, Jingru, Zhou, Gaiyan, Yang, Ning, Wang, Zhenfu, Yuan, Canxing, Tian, Zuojun, Chen, Juping, Shen, Lihua, Zheng, Huifen, Zhao, Yang, Wang, Haidong, Liu, Weiguo, and Liu, Zhenguo
- Subjects
- *
DRUG therapy for Parkinson's disease , *RESEARCH , *RESEARCH methodology , *EVALUATION research , *GERIATRIC Depression Scale , *TREATMENT effectiveness , *SEVERITY of illness index , *COMPARATIVE studies , *RANDOMIZED controlled trials , *PARKINSON'S disease , *BLIND experiment , *MENTAL depression , *QUALITY of life , *RESEARCH funding , *LONGITUDINAL method , *THIAZOLES , *DISEASE complications - Abstract
Background and Objective: Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson's disease (PD), is usually used as an add-on drug with some antiparkinsonian drugs in China. The objectives of this study were to evaluate the efficacy, safety, and tolerability of ZPG combined with pramipexole in the treatment of depression in PD (dPD).Methods: A 12-week, multicenter, randomized, double-blind, and placebo-controlled study on ZPG was performed on a total of 200 patients who were treated with pramipexole but still had mild to moderate depressive symptoms. Patients were randomly divided into ZPG (n = 100) or placebo (n = 100). The primary effective result was the mean change from the baseline on the Hamilton Depression Scale 17 items (HAM-D-17) over 12 weeks and the clinical efficacy rate. Secondary endpoints were the mean change from the baseline in the Geriatric Depression Scale (GDS-15), Unified Parkinson's disease rating scale Part III (UPDRS III), Parkinson's quality of life scale (PDQ-8), and Parkinson's disease sleep scale (PDSS-2) over 12 weeks.Results: After 12 weeks of treatment, ZPG significantly reduced the mean [95% confidence interval] HAMD score vs. placebo (- 1.43 scores [- 2.50, - 0.36]; p = 0.009). The clinical remission rate and responders of the ZPG group were higher than those of the placebo (46.1% vs. 31.0%; p = 0.041; 34.8% vs. 18.4%; p = 0.014). A significant improvement in the PDSS-2 score was also observed in the ZPG group compared with that in the placebo group (- 3.56 scores [- 5.77, - 1.35]; p = 0.002). A total of 7 patients (7.1%) in the ZPG group had mild adverse events (AEs) vs 9 patients (9%) in the placebo group. No severe AEs were observed in either group. The randomization and controlled clinical study revealed that ZPG was effective, safe, and well-tolerated.Conclusion: ZPG combined with pramipexole further reduced the depressive symptoms and improved the sleeping quality of PD patients. Trial registration The protocol was retrospectively registered at the Chinese Clinical Trial Registry, Unique identifier: ChiCTR1800019942, date of registration: December 9, 2018; http://www.chictr.org.cn/showproj.aspx?proj=30432. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
23. Fostering shared decision-making about prostate cancer screening among African American men patients and their primary care providers: a randomized behavioral clinical trial.
- Author
-
Echeverri, Margarita, Felder, Kyazia, Anderson, David, Apantaku, Elora, Leung, Patrick, Hoff, Clare, and Dennar, Princess
- Subjects
- *
PROSTATE tumors treatment , *RESEARCH , *RESEARCH methodology , *EARLY detection of cancer , *EVALUATION research , *PRIMARY health care , *COMPARATIVE studies , *RANDOMIZED controlled trials , *DECISION making , *RESEARCH funding , *PROSTATE-specific antigen , *PROSTATE tumors , *AFRICAN Americans - Abstract
Background: Prostate cancer is the third most prevalent cancer in the American population. Furthermore, the prognosis is worse in African American as there is increased morbidity and mortality associated with it.Purpose: The purpose of this study is to evaluate the effectiveness of a new online method to educate the patient population regarding prostate cancer risk, diagnosis, treatments, and their decisions about whether to be screened for the early detection of prostate cancer.Methods: Two hundred Black male patients are recruited from different clinical sites and randomized to either the control arm (usual care) or the intervention arm (educational program). We will compare the effectiveness of the intervention to see if patients are discussing the need of getting a prostate-specific antigen (PSA) test, and the possible benefits and harms that may result of having or not having the test, with their primary care providers.Discussion: Shared decision-making (SDM) is the current standard in most cancer-screening guidelines and also a standard of person-centered care. However, there is a lack of evidence-based approaches to improve decision quality in clinical settings and an increased ambiguity of applying SDM for PSA-based screening among Black men in primary care. Our proposal to evaluate a decisional-aid intervention and measure the actual application of SDM during clinical encounters has a high potential to advance the translation path of implementing shared decision-making in clinical settings and provide evidence of the applicability of the guideline in general.Innovation and Overall Impact: Given the 2018 USPSTF updated guidelines recommending shared decision-making about PSA-based screening, the increased risk of prostate cancer mortality in Black men, the challenges of evidence-based decision-making due to the underrepresentation of Blacks in major randomized clinical trials, and implicit racial bias among primary care providers, the time is ripe for interventions to improve shared decision-making about prostate cancer screening in Black men. In this study, we address communication and knowledge gaps between Black men and their primary care providers. The intervention, if proven effective, can be readily scaled across primary care practices across the U.S. and may be adapted to other types of cancer where guidelines have included shared decision-making as well. Early detection of prostate cancer may decrease mortality and morbidity in the long term. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
24. Cost-effectiveness of physiotherapy in childhood functional constipation: a randomized controlled trial in primary care.
- Author
-
Summeren, Jojanneke J G T van, Holtman, Gea A, Leeuwen, Yvonne Lisman-van, Ulsen-Rust, Alice H C van, Vermeulen, Karin M, Tabbers, Merit M, Kollen, Boudewijn J, Dekker, Janny H, Berger, Marjolein Y, van Summeren, Jojanneke J G T, Lisman-van Leeuwen, Yvonne, and van Ulsen-Rust, Alice H C
- Subjects
- *
RESEARCH , *CONSTIPATION , *PHYSICAL therapy , *RESEARCH methodology , *EVALUATION research , *TREATMENT effectiveness , *COST benefit analysis , *PRIMARY health care , *COMPARATIVE studies , *RANDOMIZED controlled trials , *RESEARCH funding - Abstract
Objective: Health care expenditures for children with functional constipation (FC) are high, while conservative management is successful in only 50% of the children. The aim is to evaluate whether adding physiotherapy to conventional treatment (CT) is a cost-effective strategy in the management of children with FC aged 4-18 years in primary care.Methods: A cost-effectiveness analysis was performed alongside a randomized controlled trial (RCT) with 8-month follow-up. Costs were assessed from a societal perspective, effectiveness included both the primary outcome (treatment success defined as the absence of FC and no laxative use) and the secondary outcome (absence of FC irrespective of laxative use). Uncertainty was assessed by bootstrapping and cost-effectiveness acceptability curves (CEACs) were displayed.Results: One hundred and thirty-four children were randomized. The incremental cost-effectiveness ratio (ICER) for one additional successfully treated child in the physiotherapy group compared with the CT group was €24,060 (95% confidence interval [CI] €-16,275 to €31,390) and for the secondary outcome €1,221 (95% CI €-12,905 to €10,956). Subgroup analyses showed that for children with chronic laxative use the ICER was €2,134 (95% CI -24,975 to 17,192) and €571 (95% CI 11 to 3,566), respectively. At a value of €1,000, the CEAC showed a probability of 0.53 of cost-effectiveness for the primary outcome, and 0.90 for the secondary outcome.Conclusions: Physiotherapy added to CT as first-line treatment for all children with FC is not cost-effective compared with CT alone. Future studies should consider the cost-effectiveness of physiotherapy added to CT in children with chronic laxative use.Trial Registration: The RCT is registered in the Netherlands Trial Register (NTR4797), on the 8th of September 2014. The first child was enrolled on the 2nd of December 2014. https://www.trialregister.nl/trial/4654. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
25. Microfluidic preparation of spermatozoa for ICSI produces similar embryo quality to density-gradient centrifugation: a pragmatic, randomized controlled trial.
- Author
-
Quinn, Molly M, Ribeiro, Salustiano, Juarez-Hernandez, Flor, Simbulan, Rhodel K, Jalalian, Liza, Cedars, Marcelle I, and Rosen, Mitchell P
- Subjects
- *
INFERTILITY treatment , *RESEARCH , *FERRANS & Powers Quality of Life Index , *BIRTH rate , *SEMEN , *RESEARCH methodology , *EVALUATION research , *INFERTILITY , *COMPARATIVE studies , *RANDOMIZED controlled trials , *IMPACT of Event Scale , *FERTILIZATION in vitro , *SPERMATOZOA , *MICROFLUIDICS , *LONGITUDINAL method , *CENTRIFUGATION - Abstract
Study Question: Does processing of spermatozoa for IVF with ICSI by a microfluidic sperm separation device improve embryo quality compared with density-gradient centrifugation?Summary Answer: Patients randomized to microfluidic sperm preparation had similar cleavage- and blastocyst-stage embryo quality and clinical and ongoing pregnancy rates to those who underwent standard sperm processing for IVF with ICSI.What Is Known Already: Microfluidic sperm preparation can isolate spermatozoa for clinical use with minimal DNA fragmentation but with unclear impact on clinical outcomes.Study Design, Size, Duration: A prospective randomized controlled trial of 386 patients planning IVF from June 2017 through September 2021 was carried out.Participants/materials, Setting, Methods: One hundred and ninety-two patients were allocated to sperm processing with a microfluidic sperm separation device for ICSI, while 194 patients were allocated to clinical standard density-gradient centrifugation (control) at an academic medical centre.Main Results and the Role Of Chance: In an intention to treat analysis, there were no differences in high-quality cleavage-stage embryo fraction [66.0 (25.8)% control versus 68.0 (30.3) microfluidic sperm preparation, P = 0.541, absolute difference -2.0, 95% CI (-8.5, 4.5)], or high-quality blastocyst fraction [37.4 (25.4) control versus 37.4 (26.2) microfluidic sperm preparation, P = 0.985, absolute difference -0.6 95% CI (-6, 5.9)] between groups. There were no differences in the clinical pregnancy or ongoing pregnancy rates between groups.Limitations, Reasons For Caution: The population studied was inclusive and did not attempt to isolate male factor infertility cases or patients with a history of elevated sperm DNA fragmentation.Wider Implications Of the Findings: Microfluidic sperm separation performs similarly to density-gradient centrifugation in sperm preparation for IVF in an unselected population.Study Funding/competing Interest(s): No external funding to declare. M.P.R. is a member of the Clinical Advisory Board for ZyMōt® Fertility, Inc.Trial Registration Number: NCT03085433.Trial Registration Date: 21 March 2017.Date Of First Patient’s Enrollment: 16 June 2017. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
26. Effectiveness of a resilience-targeted intervention based on "I have, I am, I can" strategy on nursing home older adults' suicidal ideation: A randomized controlled trial.
- Author
-
Zhang, Dan, Tian, Yinong, Wang, Rui, Wang, Lanzhong, Wang, Peng, and Su, Yonggang
- Subjects
- *
SUICIDAL ideation , *MENTAL health services , *OLDER people , *RANDOMIZED controlled trials , *NURSING home patients , *PSYCHOLOGICAL resilience , *REMINISCENCE therapy , *SUICIDE , *RESEARCH , *SELF-evaluation , *RESEARCH methodology , *EVALUATION research , *NURSING care facilities , *COMPARATIVE studies , *ANXIETY - Abstract
Background: Despite the potential for benefit, resilience remains an emergent area in late-life mental health care, and evidence of resilience intervention for suicide among nursing home residents is especially limited. This study aims to evaluate the effects of a resilience-targeted program based on the "I have, I am, and I can" strategy on suicidal ideation and related problems.Methods: From the 562 nursing home residents who were contacted, 68 with suicidal ideation were recruited and then randomly assigned to a resilience intervention group (eight-week resilience training; n = 34) or a wait-list control group (eight-week health education; n = 34). Self-reported suicidal ideation, and depression and anxiety symptoms as outcomes, and resilience as potential mediators were assessed at baseline, postintervention, and one-month follow-up.Results: Resilience training participants reported significant improvement in suicidal ideation (group × time interaction x2=12.564, p = 0.002) and depression symptoms (x2=9.441, p = 0.009) compared to wait-list control group participants. Changes in resilience mediated the intervention's effects on changes in suicidal ideation and depression symptoms. Limitations The observed effects must be considered preliminary due to the small sample size.Conclusions: The findings support the benefits of resilience training based on the "I have, I am, and I can" strategy in reducing suicidal ideation and suicide-related symptoms in nursing home older adults, and provide insight into possible mechanisms. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
27. Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.
- Author
-
Ghazi, Lama, Yamamoto, Yu, Riello, Ralph J., Coronel-Moreno, Claudia, Martin, Melissa, O'Connor, Kyle D., Simonov, Michael, Huang, Joanna, Olufade, Temitope, McDermott, James, Dhar, Ravi, Inzucchi, Silvio E., Velazquez, Eric J., Wilson, F. Perry, Desai, Nihar R., and Ahmad, Tariq
- Subjects
- *
CLUSTER randomized controlled trials , *HEART failure , *MEDICAL prescriptions , *OUTPATIENTS , *MYOCARDIAL depressants , *LEFT heart ventricle , *RESEARCH , *LEFT ventricular dysfunction , *RESEARCH methodology , *EVALUATION research , *TYPE 2 diabetes , *COMPARATIVE studies , *RANDOMIZED controlled trials , *RESEARCH funding , *STROKE volume (Cardiac output) , *HEART physiology , *CARDIOTONIC agents , *ELECTRONICS - Abstract
Background: The use of guideline-directed medical therapy (GDMT) is underprescribed in patients with heart failure with reduced ejection fraction (HFrEF).Objectives: This study sought to examine whether targeted and tailored electronic health record (EHR) alerts recommending GDMT in eligible patients with HFrEF improves GDMT use.Methods: PROMPT-HF (PRagmatic trial Of Messaging to Providers about Treatment of Heart Failure) was a pragmatic, EHR-based, cluster-randomized comparative effectiveness trial. A total of 100 providers caring for patients with HFrEF were randomized to either an alert or usual care. The alert notified providers of individualized GDMT recommendations along with patient characteristics. The primary outcome was an increase in the number of GDMT classes prescribed at 30 days postrandomization. Providers were surveyed on knowledge of guidelines and user experience.Results: The study enrolled 1,310 ambulatory patients with HFrEF from April to October 2021. Median age was 72 years; 31% were female; 18% were Black; and median left ventricular ejection fraction was 32%. At baseline, 84% of participants were receiving β-blockers, 71% received a renin-angiotensin-aldosterone system inhibitor, 29% received a mineralocorticoid receptor antagonist, and 11% received a sodium-glucose cotransporter-2 inhibitor. The primary outcome occurred in 176 of 685 (26%) participants in the alert arm vs 117 of 625 (19%) in the usual care arm, thus increasing GDMT class prescription by >40% after alert exposure (adjusted relative risk: 1.41; 95% CI: 1.03-1.93; P = 0.03). The number of patients needed to alert to result in an increase in addition of GDMT classes was 14. A total of 79% of alerted providers agreed that the alert was effective at enabling improved prescription of medical therapy for HF.Conclusions: A real-time, targeted, and tailored EHR-based alerting system for outpatients with HFrEF led to significantly higher rates of GDMT at 30 days when compared with usual care. This low-cost intervention can be rapidly integrated into clinical care and accelerate adoption of high-value therapies in heart failure. (PRagmatic trial Of Messaging to Providers about Treatment of Heart Failure [PROMPT-HF; NCT04514458]). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
28. Risk of Bias in Iranian Randomized Trials Included in Cochrane Reviews.
- Author
-
Kabir, Ali, Sofi-Mahmudi, Ahmad, Behnagh, Arman Karimi, Eidkhani, Vahid, Baradaran, Hamid Reza, Kabiri, Payam, Haghdoost, AliAkbar, and Mesgarpour, Bita
- Subjects
- *
MEDICAL databases , *SYSTEMATIC reviews , *RESEARCH methodology , *EVIDENCE-based medicine , *RANDOMIZED controlled trials , *RESEARCH bias , *STANDARDS - Abstract
Background: Among interventional studies, randomized controlled trials (RCTs) provide the highest level of evidence. However, RCTs can be susceptible to the risk of bias (RoB). Systematic reviews can be performed to appraise RoB in the included articles using evaluative tools. This study aimed to describe the main characteristics and focus on the RoB of RCTs conducted in Iran and included in Cochrane Reviews (CRs). Methods: We searched "Iran" by selecting the "Search All Text" and "Review" fields in the Cochrane Database of Systematic Reviews within Ovid. CRs that included the RCTs conducted in Iran were retrieved. A trial was selected only if it was included in CRs, described as a controlled clinical trial, involved human subjects and CR authors assessed its RoB. The trials were characterized by investigating the relevant articles and the table "Characteristics of included studies" in each CR. The RoB was investigated by collecting the review authors' judgments based on RoB assessment tables in the CRs. Results: Out of 1166 Iranian RCTs included by 571 CRs, low RoB was found in 44.9% for random sequence generation, 20.8% for allocation concealment, 32.3% for blinding of participants/personnel, 36.5% for blinding of outcome assessors, 56.3% for incomplete outcome data, 41.3% for selective outcome reporting and 53.8% for other sources of bias. Conclusion: The RoB in Iranian RCTs was found to be mostly high or unclear. While this is similar to the global situation, it is recommended that the methodological quality of conducting and reporting RCTs be addressed in Iran. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA).
- Author
-
Thriemer, Kamala, Degaga, Tamiru Shibru, Christian, Michael, Alam, Mohammad Shafiul, Ley, Benedikt, Hossain, Mohammad Sharif, Kibria, Mohammad Golam, Tego, Tedla Teferi, Abate, Dagimawie Tadesse, Weston, Sophie, Karahalios, Amalia, Rajasekhar, Megha, Simpson, Julie A., Rumaseb, Angela, Mnjala, Hellen, Lee, Grant, Anose, Rodas Temesgen, Kidane, Fitsum Getahun, Woyessa, Adugna, and Baird, Kevin
- Subjects
- *
PLASMODIUM vivax , *RANDOMIZED controlled trials , *BLOOD transfusion , *MALARIA , *DISEASE relapse , *DRUG therapy for malaria , *MALARIA diagnosis , *PROTOZOA , *RESEARCH , *RESEARCH methodology , *EVALUATION research , *COMPARATIVE studies , *PROTEINURIA , *ANTIMALARIALS , *PRIMAQUINE - Abstract
Background: Plasmodium vivax forms dormant liver stages that can reactivate weeks or months following an acute infection. Recurrent infections are often associated with a febrile illness and can cause a cumulative risk of severe anaemia, direct and indirect mortality, and onward transmission of the parasite. There is an increased risk of P. vivax parasitaemia following falciparum malaria suggesting a rationale for universal use of radically curative treatment in patients with P. falciparum malaria even in the absence of detectable P. vivax parasitaemia in areas that are co-endemic for both species.Methods: This is a multicentre, health care facility-based, randomized, controlled, open-label trial in Bangladesh, Indonesia and Ethiopia. Patients with uncomplicated falciparum malaria, G6PD activity of ≥70% of the adjusted male median (AMM) and haemoglobin levels ≥8g/dl are recruited into the study and randomized to either receive standard schizonticidal treatment plus 7-day high dose primaquine (total dose 7mg/kg) or standard care in a 1:1 ratio. Patients are followed up weekly until day 63. The primary endpoint is the incidence risk of any P. vivax parasitemia on day 63. Secondary endpoints include incidence risk on day 63 of symptomatic P. vivax malaria and the risk of any P. falciparum parasitaemia. Secondary safety outcomes include the proportion of adverse events and serious adverse events, the incidence risk of severe anaemia (Hb<5g/dl and <7g/dl) and/or the risk for blood transfusion, the incidence risk of ≥ 25% fall in haemoglobin with and without haemoglobinuria, and the incidence risk of ≥ 25% fall in haemoglobin to under 7g/dl with and without haemoglobinuria.Discussion: This study evaluates the potential benefit of a universal radical cure for both P. vivax and P. falciparum in different endemic locations. If found safe and effective universal radical cure could represent a cost-effective approach to clear otherwise unrecognised P. vivax infections and hence accelerate P. vivax elimination.Trial Registration: NCT03916003 . Registered on 12 April 2019. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
30. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial.
- Author
-
Diederichsen, Axel C.P., Lindholt, Jes S., Möller, Sören, Øvrehus, Kristian A., Auscher, Søren, Lambrechtsen, Jess, Hosbond, Susanne E., Alan, Dilek H., Urbonaviciene, Grazina, Becker, Søren W., Fredgart, Maise H., Hasific, Selma, Folkestad, Lars, Gerke, Oke, Rasmussen, Lars Melholt, Møller, Jacob E., Mickley, Hans, and Dahl, Jordi S.
- Subjects
- *
THERAPEUTIC use of vitamin D , *RESEARCH , *RESEARCH methodology , *AORTIC stenosis , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *CALCINOSIS , *AORTIC valve , *VITAMIN K ,AORTIC valve surgery - Abstract
Background: Menaquinone-7 (MK-7), also known as vitamin K2, is a cofactor for the carboxylation of proteins involved in the inhibition of arterial calcification and has been suggested to reduce the progression rate of aortic valve calcification (AVC) in patients with aortic stenosis.Methods: In a randomized, double-blind, multicenter trial, men from the community with an AVC score >300 arbitrary units (AU) on cardiac noncontrast computer tomography were randomized to daily treatment with tablet 720 µg MK-7 plus 25 µg vitamin D or matching placebo for 24 months. The primary outcome was the change in AVC score. Selected secondary outcomes included change in aortic valve area and peak aortic jet velocity on echocardiography, heart valve surgery, change in aortic and coronary artery calcification, and change in dp-ucMGP (dephosphorylated-undercarboxylated matrix Gla-protein). Safety outcomes included all-cause death and cardiovascular events.Results: From February 1, 2018, to March 21, 2019, 365 men were randomized. Mean age was 71.0 (±4.4) years. The mean (95% CI) increase in AVC score was 275 AU (95% CI, 225-326 AU) and 292 AU (95% CI, 246-338 AU) in the intervention and placebo groups, respectively. The mean difference on AVC progression was 17 AU (95% CI, -86 to 53 AU; P=0.64). The mean change in aortic valve area was 0.02 cm2 (95% CI, -0.09 to 0.12 cm2; P=0.78) and in peak aortic jet velocity was 0.04 m/s (95% CI, -0.11 to 0.02 m/s; P=0.21). The progression in aortic and coronary artery calcification score was not significantly different between patients treated with MK-7 plus vitamin D and patients receiving placebo. There was no difference in the rate of heart valve surgery (1 versus 2 patients; P=0.99), all-cause death (1 versus 4 patients; P=0.37), or cardiovascular events (10 versus 10 patients; P=0.99). Compared with patients in the placebo arm, a significant reduction in dp-ucMGP was observed with MK-7 plus vitamin D (-212 pmol/L versus 45 pmol/L; P<0.001).Conclusions: In elderly men with an AVC score >300 AU, 2 years MK-7 plus vitamin D supplementation did not influence AVC progression.Registration: URL: https://www.Clinicaltrials: gov; Unique identifier: NCT03243890. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
31. Effects of CPAP on Metabolic Syndrome in Patients With OSA: A Randomized Trial.
- Author
-
Giampá, Sara Q.C., Furlan, Sofia F., Freitas, Lunara S., Macedo, Thiago A., Lebkuchen, Adriana, Cardozo, Karina H.M., Carvalho, Valdemir M., Martins, Franco C., Azam, Indira F.B., Costa-Hong, Valéria, Lopes, Heno F., Baptista, Mariana L., Rochitte, Carlos E., Bortolotto, Luiz A., Lorenzi-Filho, Geraldo, and Drager, Luciano F.
- Subjects
- *
METABOLIC syndrome , *BODY composition , *ABDOMINAL adipose tissue , *FOOD consumption , *PHYSICAL activity , *WAIST-hip ratio , *SKINFOLD thickness , *OBESITY complications , *SLEEP apnea syndrome treatment , *RESEARCH , *CONTINUOUS positive airway pressure , *LEPTIN , *RESEARCH methodology , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *SLEEP apnea syndromes , *ADIPONECTIN , *STATISTICAL sampling , *LIPIDS , *DISEASE complications - Abstract
Background: OSA is associated with metabolic syndrome (MS), but it is unclear whether OSA treatment with CPAP can revert MS.Research Question: Does OSA treatment with CPAP per se have effects on the MS reversibility and the associated metabolic, adiposity and vascular parameters?Study Design and Methods: The TREATOSA-MS trial is a randomized placebo-controlled trial that enrolled adult patients with a recent diagnosis of MS and moderate or severe OSA (apnea-hypopnea index [AHI], ≥ 15 events/h) to undergo therapeutic CPAP or nasal dilator strips (placebo group) for 6 months. Before and after each intervention, we measured anthropometric variables, BP, glucose, and lipid profile. To control potential-related mechanisms and consequences, we also measured adiposity biomarkers (leptin and adiponectin), body composition, food intake, physical activity, subcutaneous and abdominal fat (visceral and hepatic fat), and endothelial function.Results: One hundred patients (79% men; mean age, 48 ± 9 years; BMI, 33 ± 4 kg/m2; AHI, 58 ± 29 events/h) completed the study (n = 50 per group). The mean CPAP adherence was 5.5 ± 1.5 h/night. After 6 months, most patients with OSA randomized to CPAP retained the MS diagnosis, but the rate of MS reversibility was higher than observed in the placebo group (18% vs 4%; OR, 5.27; 95% CI, 1.27-35.86; P = .04). In the secondary analysis, CPAP did not promote significant reductions in the individual components of MS, weight, hepatic steatosis, lipid profile, adiponectin, and leptin, but did promote a very modest reduction in visceral fat and improved endothelial function (all analyses were adjusted for baseline values).Interpretation: Despite the higher rate of MS reversibility after CPAP therapy as compared with placebo, most patients retained this diagnosis. The lack of significant or relevant effects on adiposity biomarkers and depots supports the modest role of OSA in modulating MS.Trial Registration: ClinicalTrials.gov; No.: NCT02295202; URL: www.Clinicaltrials: gov. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
32. Comparison of effective phacoemulsification time and corneal endothelial cell loss using three different ultrasound frequencies: A randomized controlled trial.
- Author
-
Dewan, Taru, Malik, Praveen, Tomar, Preeti, and Malik, Praveen K
- Subjects
- *
PHACOEMULSIFICATION , *RANDOMIZED controlled trials , *ENDOTHELIAL cells , *CORNEA , *ULTRASONIC imaging , *RESEARCH , *ENDOTHELIUM , *CYTOMETRY , *CORNEA diseases , *RESEARCH methodology , *EVALUATION research , *CATARACT surgery , *COMPARATIVE studies , *LONGITUDINAL method ,CATARACT diagnosis - Abstract
Purpose: Comparison of three ultrasound (US) frequencies for phacoemulsification of hard cataracts to determine a frequency that makes phacoemulsification more efficacious and safer.Methods: A randomized controlled trial was undertaken at a medical college and hospital. In total, 207 patients with grade 5.6-6.9 (LOCS III) senile cataract were randomized into three groups. Group I underwent phacoemulsification with 28-kHz frequency, group II with 42-kHz frequency, and group III with 53-kHz frequency. The effective phacoemulsification time (EPT) and estimated fluid usage (EFU) were compared intraoperatively. The endothelial cell parameters were analyzed for 6 months.Results: The groups were matched for age (P = 0.467), gender (P = 0.497), nuclear grade (P = 0.321), and anterior chamber depth (P = 0.635). The EPT and EFU were significantly lower in group III, compared to group II and group I, with P < 0.0001 and P < 0.0001, respectively. Postoperatively, the endothelial cell density (ECD) was significantly higher in group III at 1 month (P < 0.0001), 3 months (P < 0.0001), and 6 months (P < 0.0001). The percentages of ECD loss were also significantly lower in group III; the difference was statistically significant (P < 0.0001) up to 6 months postoperatively.Conclusion: Higher frequency ultrasound was associated with a lower EPT and EFU as well as better endothelial preservation than lower frequencies in hard cataracts. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
33. Analgesic effect of perioperative duloxetine in patients after total knee arthroplasty: a prospective, randomized, double-blind, placebo-controlled trial.
- Author
-
Yuan, Mingcheng, Tang, Tingting, Ding, Zichuan, Li, Hao, and Zhou, Zongke
- Subjects
- *
TOTAL knee replacement , *DULOXETINE , *POSTOPERATIVE period , *VISUAL analog scale , *RANGE of motion of joints , *RESEARCH , *ANALGESICS , *RESEARCH methodology , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *BLIND experiment , *LONGITUDINAL method - Abstract
Background: To investigate the analgesic effect of perioperative use of duloxetine in patients received total knee arthroplasty (TKA).Method: This prospective randomized, double-blind, placebo-controlled trial study was registered in the Chinese Clinical Trial Registry (ChiCTR2000033910). 100 patients were finally enrolled. The hospital pharmacy prepared small capsules containing either duloxetine or starch (placebo) which were all identical in appearance and weight (50:50). The 100 enrolled patients were given a capsule (containing either 60 mg duloxetine or 60 mg placebo) every night before sleep since preoperative day 2 till postoperative day 14 (17 days in all) by a nurse who were not involved in this trial. Other perioperative managements were the same in the two groups. The primary outcome was the VAS score, including rVAS (visual analogue scale at rest) and aVAS (visual analogue scale upon ambulation) throughout the perioperative period. The secondary outcomes included opioid consumption, range of motion, including both active range of motion (aROM) and passive range of motion (pROM) and adverse events. The patients were followed up everyday until 7 days after TKA, afterwards, they were followed up at the time of 3 weeks and 3 months after TKA.Result: rVAS in duloxetine group were significantly less than placebo group throughout the postoperative period: 4.7 ± 2.3 vs 5.9 ± 2.6 (P = 0.016) at 24 h postoperative; 2.1 ± 1.6 vs 2.8 ± 1.7 (P = 0.037) at 7 days postoperative. In terms of aVAS, similarly, duloxetine group had less aVAS than placebo group throughout the postoperative period: 6.2 ± 2.1 vs 7.1 ± 2.2 (P = 0.039) at 24 h postoperative; 3.3 ± 1.7 vs 4.1 ± 2.0 (P = 0.034) at 7 days postoperative. Patients in duloxetine group consumed significantly less opioids per day than the placebo group: 24.2 ± 10.1 g vs 28.5 ± 8.3 g (P = 0.022) at 24 h postoperative; 2.7 ± 2.5 g vs 4.1 ± 2.6 g (P = 0.007) at 7 days postoperative. aROM in duloxetine group were significantly better than placebo group until postoperative day 6, the aROM became comparable between the two groups: 110.2 ± 9.9° in duloxetine group vs 107.5 ± 11.5° in control group (P = 0.211). In terms of pROM, duloxetine group had significantly better pROM until postoperative day 5, the pROM became comparable between the two groups: 103.8 ± 12.1° in duloxetine group vs 99.5 ± 10.8° in control group (P = 0.064). No significant difference was found between the two groups in the rates of dizziness, bleeding, sweating, fatigue and dryness of mouth. In the placebo group, more patients got nausea/vomiting and constipation (P < 0.05). However, in terms of drowsiness, duloxetine group was reported higher rate (P < 0.05).Conclusion: Several other RCTs have already mentioned the analgesic effect of duloxetine, but not in the immediate postoperative period. In this study, we found duloxetine could reduce acute postoperative pain in the immediate postoperative period and decrease the opioids consumption as well as accelerating postoperative recovery, without increasing the risk of adverse medication effects in patients undergoing TKA. Duloxetine could act as a good supplement in multimodal pain management protocol for patients undergoing TKA.Trial Registration Statement: This study was registered in the Chinese Clinical Trial Registry (ChiCTR2000033910). The date of registration was 06/16/2020. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
34. Lactobacillus casei modulates inflammatory cytokines and metabolites during tuberculosis treatment: A post hoc randomized controlled trial.
- Author
-
Lan Jiang, Jinyu Wang, Lei Xu, Jing Cai, Shanliang Zhao, Aiguo Ma, Jiang, Lan, Wang, Jinyu, Xu, Lei, Cai, Jing, Zhao, Shanliang, and Ma, Aiguo
- Subjects
- *
THERAPEUTIC use of probiotics , *TUBERCULOSIS treatment , *CYTOKINES , *RESEARCH , *RESEARCH methodology , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *LACTOBACILLUS - Abstract
Background and Objectives: Inflammatory cytokines and metabolic abnormalities are common in patients with tuberculosis. Observational studies have indicated that probiotics modulate inflammatory cytokines and metabolites; however, clinical evidence of the effect of probiotics on patients with tuberculosis is lacking. This study investigated the effects of Lactobacillus casei on inflammatory cytokines and metabolites during tuberculosis treatment.Methods and Study Design: A randomized controlled trial was conducted. A total of 47 inpatients were included and randomly assigned to receive standard antituberculosis therapy only (control group) or that treatment together with 1 × 1010 colony-forming units per day of Lactobacillus casei (low-dose group) or 2 × 1010 colony-forming units per day of Lactobacillus casei (high-dose group) for 4 weeks of intensive treatment during hospitalization. Plasma samples were analyzed for inflammatory cytokines and metabolomics with ELISA kits and ultrahigh performance liquid chromatography quadrupole time-of-flight mass spectrometry.Results: Daily Lactobacillus casei supplementation of up to 2 × 1010 colony-forming units significantly lowered the concentrations of tumor necrosis factor-α, interleukin-6, interleukin-10, and interleukin-12 (p=0.007, p=0.042, p=0.002, p<0.001, respectively) in patients with tuberculosis. Compared with the control and low-dose groups, the plasma metabolites of phosphatidylserine, maresin 1, phosphatidylcholine, L-saccharopine, and pyridoxamine were significantly upregulated, and N-acetylmethionine, L-tryptophan, phosphatidylethanolamine, and phenylalanine were downregulated in the high-dose group. Strong correlations were observed between metabolites and inflammatory cytokines.Conclusions: Lactobacillus casei supplementation during the intensive phase of tuberculosis treatment can significantly modulate inflammatory cytokines and metabolites. Decreased inflammatory cytokines may be related to metabolite changes. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
35. Physicians' Choice of Board Certification Activity Is Unaffected by Baseline Quality of Care: The TRADEMaRQ Study.
- Author
-
Peterson, Lars E., Johannides, John, Phillips Jr., Robert L., and Phillips, Robert L Jr
- Subjects
- *
PHYSICIANS , *CERTIFICATION , *BIVARIATE analysis , *AFFINITY groups , *RESEARCH , *FERRANS & Powers Quality of Life Index , *RESEARCH methodology , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *CLINICAL competence , *QUALITY assurance , *RESEARCH funding - Abstract
Purpose: Physicians' use of self-assessment to guide quality improvement or board certification activities often does not correlate with more objective measures, and they may spend valuable time on activities that support their strengths instead of addressing gaps. Our objective was to study whether viewing quality measures, with peer comparisons, would affect the selection of certification activities.Methods: We conducted a cluster-randomized controlled trial-the Trial of Data Exchange for Maintenance of certification and Raising Quality (TRADEMaRQ)-with 4 partner organizations during 2015-2017. Physicians were presented their quality data within their online certification portfolios before (intervention) vs after (control) they chose board certification activities. The primary outcome was whether the selected activity addressed a quality gap (a quality area in which the physician scored below the mean for the study population).Results: Of 2,570 invited physicians, 254 physicians completed the study: 130 in the intervention group and 124 in the control group. Nearly one-fifth of participating physicians did not complete any certification activities during the study. A sizable minority of those in the intervention group, 18.4%, never reviewed their quality dashboard. Overall, just 27.2% of completed certification activities addressed a quality gap, and there was no significant difference in this outcome in the intervention group vs the control group in either bivariate or adjusted analyses (odds ratio = 1.28; 95% CI, 0.90-1.82).Conclusions: Physicians did not use quality performance data in choosing certification activities. Certification boards are being pressed to make their programs relevant to practice, less burdensome, and supportive of quality improvement in alignment with value-based payment models. Using practice data to drive certification choices would meet these goals. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
36. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.
- Author
-
Cornblath, David R, Doorn, Pieter A van, Hartung, Hans-Peter, Merkies, Ingemar S J, Katzberg, Hans D, Hinterberger, Doris, Clodi, Elisabeth, Investigators, the ProCID, van Doorn, Pieter A, and ProCID Investigators
- Subjects
- *
RESEARCH , *CLINICAL trials , *RESEARCH methodology , *EVALUATION research , *TREATMENT effectiveness , *COMPARATIVE studies , *RANDOMIZED controlled trials , *GUILLAIN-Barre syndrome , *BLIND experiment , *LONGITUDINAL method - Abstract
Intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy usually starts with a 2.0 g/kg induction dose followed by 1.0 g/kg maintenance doses every 3 weeks. No dose-ranging studies with intravenous immunoglobulin maintenance therapy have been published. The Progress in Chronic Inflammatory Demyelinating polyneuropathy (ProCID) study was a prospective, double-blind, randomized, parallel-group, multicentre, phase III study investigating the efficacy and safety of 10% liquid intravenous immunoglobulin (Panzyga®) in patients with active chronic inflammatory demyelinating polyneuropathy. Patients were randomized 1:2:1 to receive the standard intravenous immunoglobulin induction dose and then either 0.5, 1.0 or 2.0 g/kg maintenance doses every 3 weeks. The primary end point was the response rate in the 1.0 g/kg group, defined as an improvement ≥1 point in adjusted Inflammatory Neuropathy Cause and Treatment score at Week 6 versus baseline and maintained at Week 24. Secondary end points included dose response and safety. This trial was registered with EudraCT (Number 2015-005443-14) and clinicaltrials.gov (NCT02638207). Between August 2017 and September 2019, the study enrolled 142 patients. All 142 were included in the safety analyses. As no post-infusion data were available for three patients, 139 were included in the efficacy analyses, of whom 121 were previously on corticosteroids. The response rate was 80% (55/69 patients) [95% confidence interval (CI): 69-88%] in the 1.0 g/kg group, 65% (22/34; CI: 48-79%) in the 0.5 g/kg group, and 92% (33/36; CI: 78-97%) in the 2.0 g/kg group. While the proportion of responders was higher with higher maintenance doses, logistic regression analysis showed that the effect on response rate was driven by a significant difference between the 0.5 and 2.0 g/kg groups, whereas the response rates in the 0.5 and 2.0 g/kg groups did not differ significantly from the 1.0 g/kg group. Fifty-six per cent of all patients had an adjusted Inflammatory Neuropathy Cause and Treatment score improvement 3 weeks after the induction dose alone. Treatment-related adverse events were reported in 16 (45.7%), 32 (46.4%) and 20 (52.6%) patients in the 0.5, 1.0 and 2.0 g/kg dose groups, respectively. The most common adverse reaction was headache. There were no treatment-related deaths. Intravenous immunoglobulin (1.0 g/kg) was efficacious and well tolerated as maintenance treatment for patients with chronic inflammatory demyelinating polyneuropathy. Further studies of different maintenance doses of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
- Author
-
Planquette, Benjamin, Bertoletti, Laurent, Charles-Nelson, Anaïs, Laporte, Silvy, Grange, Claire, Mahé, Isabelle, Pernod, Gilles, Elias, Antoine, Couturaud, Francis, Falvo, Nicolas, Sevestre, Marie Antoinette, Ray, Valérie, Burnod, Alexis, Brebion, Nicolas, Roy, Pierre-Marie, Timar-David, Miruna, Aquilanti, Sandro, Constans, Joel, Bura-Rivière, Alessandra, and Brisot, Dominique
- Subjects
- *
RIVAROXABAN , *LOW-molecular-weight heparin , *THROMBOEMBOLISM , *DISEASE relapse , *PULMONARY embolism , *ENOXAPARIN , *RESEARCH , *VEINS , *CLINICAL trials , *RESEARCH methodology , *ANTICOAGULANTS , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *TUMORS , *STATISTICAL sampling , *HEMORRHAGE , *DISEASE complications - Abstract
Background: Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight heparin for treating cancer-associated VTE.Research Question: Is rivaroxaban as efficient and safe as dalteparin to treat patients with cancer-associated VTE?Study Design and Methods: In a randomized open-label noninferiority trial, patients with active cancer who had proximal DVT, pulmonary embolism (PE), or both were assigned randomly to therapeutic doses of rivaroxaban or dalteparin for 3 months. The primary outcome was the cumulative incidence of recurrent VTE, a composite of symptomatic or incidental DVT or PE, and worsening of pulmonary vascular or venous obstruction at 3 months.Results: Of 158 randomized patients, 74 and 84 patients were assigned to receive rivaroxaban and dalteparin, respectively. Mean age was 69.4 years, and 115 patients (76.2%) had metastatic disease. The primary outcome occurred in 4 and 6 patients in the rivaroxaban and dalteparin groups, respectively (both the intention-to-treat and per-protocol populations: cumulative incidence, 6.4% vs 10.1%; subdistribution hazard ratio [SHR], 0.75; 95% CI, 0.21-2.66). Major bleeding occurred in 1 and 3 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence, 1.4% vs 3.7%; SHR, 0.36; 95% CI, 0.04-3.43). Major or clinically relevant nonmajor bleeding occurred in 9 and 8 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence, 12.2% vs 9.8%; SHR, 1.27; 95% CI, 0.49-3.26). Overall, 19 patients (25.7%) and 20 patients (23.8%) died in the rivaroxaban and dalteparin groups, respectively (hazard ratio, 1.05; 95% CI, 0.56-1.97).Interpretation: In this trial comparing rivaroxaban and dalteparin in the treatment of cancer-associated VTE, the number of patients was insufficient to reach the predefined criteria for noninferiority, but efficacy and safety results were consistent with those previously reported with DOACs. An updated meta-analysis of randomized trials comparing DOACs with low-molecular-weight heparin in patients with cancer-associated VTE is provided.Trial Registry: ClinicalTrials.gov; No.: NCT02746185; URL: www.Clinicaltrials: gov. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
38. Implementation fidelity of a transition program for adolescents with congenital heart disease: the STEPSTONES project.
- Author
-
Saarijärvi, Markus, Wallin, Lars, Moons, Philip, Gyllensten, Hanna, and Bratt, Ewa-Lena
- Subjects
- *
CONGENITAL heart disease , *TEENAGERS , *MEDICAL personnel , *STANDARD operating procedure , *CHRONIC diseases , *EXPERIMENTAL design , *RESEARCH , *RESEARCH methodology , *SOCIAL networks , *MEDICAL care , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *PSYCHOLOGICAL tests , *RESEARCH funding - Abstract
Background: Although transition programs have been evaluated for adolescents with chronic conditions, these have rarely involved process evaluations. Indeed, outcomes of complex interventions are dependent on how the intervention is implemented in practice and evaluations of implementation process are therefore pivotal. The aim of this study was to evaluate the extent to which a transition program for adolescents with congenital heart disease was delivered as intended. Research questions were 1) to what level of fidelity was the program delivered? and 2) what potential moderating factors affected the delivery of the program and overall fidelity?Methods: A mixed methods design was used, where a process evaluation was embedded in the STEPSTONES randomized controlled trial in Sweden. The implementation fidelity framework by Carrol (2007) and Hasson (2010) was used to design, collect and analyze data. Quantitative data consisted of intervention records on adherence and were analyzed with descriptive statistics. Qualitative data on moderators affecting fidelity were collected through interviews, log-books and focus group interviews with healthcare professionals implementing the intervention and participatory observations of the implementation process. Data were analyzed with deductive content analysis. Triangulation was used to integrate quantitative and qualitative data within the fidelity framework.Results: Six out of eight components of the transition program were delivered to an extent that adhered to the program theory or achieved a high level of fidelity. However, components involving peer support had a low attendance by the participating sample (32.2%), and the joint transfer meeting was challenging to implement, despite achieving high adherence. Moderators affecting the implementation process were the adolescent's and healthcare professional's engagement in the intervention, contextual factors and a lack of standard operating procedures for all components in the program.Conclusion: Barriers and facilitators for a future implementation of transition programs have been illuminated in this study. The use of an implementation fidelity framework in the process evaluation proved successful in providing a comprehensive evaluation of factors affecting the implementation process. However, implementation fidelity must be considered in relation to adaptations to the local and personal prerequisites in order to create interventions that can achieve fit. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
39. Adjunctive Topical Tranexamic Acid for Blood Salvage Does Not Reduce Postoperative Blood Loss Compared with Placebo in Patients Who Undergo Palliative Decompressive Spinal Metastasis Surgery: A Randomized Controlled Trial.
- Author
-
Maethungkul, Ronnakrit, Atthakomol, Pichitchai, Phinyo, Phichayut, Phanphaisarn, Areerak, Murakami, Hideki, and Sangsin, Apiruk
- Subjects
- *
SPINAL surgery , *AUTOTRANSFUSION of blood , *TRANEXAMIC acid , *RANDOMIZED controlled trials , *SPINAL cord compression , *BLOOD transfusion , *PLACEBOS , *SURGICAL blood loss , *RESEARCH , *RESEARCH methodology , *SURGICAL complications , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *ANTIFIBRINOLYTIC agents , *CUTANEOUS therapeutics , *SPINAL tumors , *HEMORRHAGE - Abstract
Study Design: Randomized controlled trial.Objective: To evaluate the efficacy of adjunctive topical tranexamic acid (tTXA) in reducing postoperative blood loss and packed red cell (PRC) transfusion in patients who underwent palliative decompressive spinal metastasis surgery for malignant epidural spinal cord compression.Summary Of Background Data: Palliative decompressive spinal metastasis surgery is associated with massive postoperative blood loss and increased transfusion rate. tTXA reduces blood loss in traumatic or degenerative spinal surgery; however, the role of topical TXA in decompressive spinal metastasis surgery remains controversial.Method: A total of 65 patients who underwent palliative decompressive thoracolumbar spinal metastasis surgery were included in this study. In 33 patients, 1 g of tTXA (20 mL) was soaked in an absorbable gelatin sponge and placed lateral to the decompressive site. The remaining 32 patients in the control group received the same procedures with normal saline at the same volume, instead of TXA. All of the patients received standard 1 g intravenous TXA, just before initiating the operation. The primary outcome was postoperative blood loss, and the secondary outcomes were postoperative PRC transfusion and complications.Results: No differences were found in postoperative blood loss between tTXA and placebo group (P50 778 mL [IQR 347, 1,122 mL] versus P50 490 mL [IQR 295, 920 mL]; P = 0.238). The number of patients requiring postoperative PRC transfusion were quite similar in tTXA and placebo groups (PRC transfusion in 15 patients [45.45%] versus 16 patients [50%]; P = 0.585). No complications related to TXA and absorbable gelatin sponge were observed.Conclusion: We do not recommend tTXA as an adjunctive treatment for patients undergoing decompressive spinal metastasis surgery since it does not provide additional benefit to prophylactic intravenous TXA in postoperative blood loss and transfusion rate.Level of Evidence: 2. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
40. Use of coping strategies in the management of medication overuse headache.
- Author
-
Mose, Louise Schlosser, Jensen, Rigmor Højland, Nygaard, Niels-Peter Brøchner, Pedersen, Susanne Schmidt, and Gram, Bibi
- Subjects
- *
MEDICATION overuse headache , *MEDICATION therapy management , *COPING Strategies Questionnaire , *MOTIVATIONAL interviewing , *PSYCHOLOGICAL adaptation , *MYOCARDIAL infarction , *HEADACHE treatment , *RESEARCH , *PAIN , *RESEARCH methodology , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *QUESTIONNAIRES , *HEADACHE , *STATISTICAL sampling - Abstract
Objectives: Use of Motivational Interviewing (MI) in education may improve medication-overuse headache (MOH) patients' ability to cope with pain. In a randomised controlled trial, we evaluated the effect of education focusing on behavioural change among MOH patients.Methods: Ninety-eight MOH patients were randomized (1:1) to standard treatment and 12-weeks of MI-based education versus standard treatment alone after detoxification. Outcome of interest was changes in coping strategies measured by the Coping Strategy Questionnaire at four- and nine months.Results: The educational program improved patients' perceived efficacy in the use of their coping strategies to control pain, both at four-and nine months follow-up (mean±SE): ∆:0.84 ± 0.35, 95% CI:0.16;1.52, p = 0.02 and: ∆: 0.90 ± 0.39, 95% CI:0.14;1.66, p = 0.02, respectively. No between-group differences were detected in the other coping subscales. Within the intervention group, the coping strategy subscales Catastrophizing, and Reinterpretation of pain sensation were significantly improved at nine months follow-up (p = 0.003 vs. p = 0.012, respectively). No changes were found in the control group.Conclusion: MI-based education focused on behavioural changes improved MOH patients' perceived efficacy in the use of their coping strategies to control pain.Practice Implications: Education based on MI could be valuable for MOH patients with respect to behavioural changes and perceived headache control. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
41. In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial.
- Author
-
Zheng, Xiaoying, Guo, Wei, Zeng, Lin, Zheng, Danni, Yang, Shuo, Xu, Yalan, Wang, Lina, Wang, Rui, Mol, Ben Willem, Li, Rong, and Qiao, Jie
- Subjects
- *
INDUCED ovulation , *OVARIAN hyperstimulation syndrome , *FERTILIZATION in vitro , *POLYCYSTIC ovary syndrome , *HUMAN in vitro fertilization , *RESEARCH & development , *RANDOMIZED controlled trials , *REPRODUCTIVE technology , *PREGNANCY outcomes , *POLYCYSTIC ovary syndrome treatment , *INFERTILITY treatment , *RESEARCH , *BIRTH rate , *RESEARCH methodology , *EVALUATION research , *INFERTILITY , *GONADOTROPIN , *COMPARATIVE studies , *RESEARCH funding , *DISEASE complications - Abstract
Study Question: Does in vitro maturation (IVM) result in non-inferior cumulative live birth rates compared to those after standard in vitro fertilization (IVF) in infertile women with polycystic ovary syndrome (PCOS)?Summary Answer: One cycle of IVM, without any stimulation, was inferior to one cycle of standard IVF in women with PCOS in terms of 6-month cumulative live birth rates, when choosing single vitrified-warmed blastocyst transfer.What Is Known Already: IVM is an emerging alternative treatment for women with PCOS who need assisted reproductive technology. Since a minimal or even zero dose of gonadotropins are required in the IVM procedure, the occurrence of ovarian hyperstimulation syndrome (OHSS) is eliminated. Only one clinical trial comparing the pregnancy outcome between IVM with FSH priming and IVF has been reported. However, it is still unknown whether IVM treatment without any stimulation can offer a similar live birth outcome in women with PCOS as compared to that in women receiving the standard IVF procedure with ovarian stimulation.Study Design, Size, Duration: This single-centre, open-label randomized controlled non-inferiority trial in an academic infertility centre in China was performed between March 2018 and July 2019.Participants/materials, Setting, Methods: Women aged 20-38 years with PCOS and infertility scheduled for their first IVF attempt were eligible. In total, 351 women were randomly allocated to receive one cycle of unstimulated IVM (n = 175) or one cycle of standard IVF with a flexible GnRH antagonist protocol and hCG as ovulatory trigger (n = 176). A freeze-all and single blastocyst transfer strategy was used in both groups. The primary outcome was ongoing pregnancy (leading to live birth) within 6 months after randomization. A non-inferiority margin of 15% was considered.Main Results and the Role Of Chance: The IVM procedure without additional gonadotropin resulted in a lower ongoing pregnancy (leading to live birth) within 6 months after randomization compared to standard IVF treatment (22.3% vs. 50.6%; rate difference -28.3%; 95% confidence interval [CI]: -37.9% to -18.7%). Moderate-severe OHSS did not occur in the IVM group, while in the IVF group, ten women (5.7%) had moderate OHSS and one woman (0.6%) had severe OHSS. There was no statistically significant difference in the occurrence of obstetric and perinatal complications.Limitations, Reasons For Caution: The trial was conducted using an IVM protocol without additional stimulation in a single centre, which may limit its generalizability. In addition, a GnRH agonist trigger rather than hCG for IVF stimulation in women with PCOS would be more consistent with current clinical practice.Wider Implications Of the Findings: Although IVM is considered to be a convenient, inexpensive and safe alternative to IVF for women with PCOS, our results indicated that one cycle of IVM without any stimulation was inferior to one cycle of standard IVF in terms of the cumulative live birth rate. The inferiority of IVM without ovarian stimulation could be mainly due to the limitations in the developmental potential of embryos. Further IVM development should be tested and validated in a freeze-only and blastocyst transfer setting. Further RCTs are needed to evaluate the effectiveness and safety of other IVM protocols or multiple cycles of IVM compared to IVF.Study Funding/competing Interest(s): This study was supported by the National Key Research and Development Program of China (2016YFC1000201 and 2018YFC1002104) and the National Science Foundation of China (81730038). B.W.M. is supported by a NHMRC Investigator grant (GNT1176437). All other authors declare no competing interests.Trial Registration Number: Clinicaltrials.gov NCT03463772.Trial Registration Date: 29 January 2018.Date Of First Patient’s Enrolment: 16 March 2018. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
42. Evaluation of the effect of analgesic treatment on signs of nociception-related behaviors during physiotherapy in patients with disorders of consciousness: a pilot crossover randomized controlled trial.
- Author
-
Bonin, Estelle A.C., Binda Fossati, Mariachiara L., Filippini, Maria M., Bornheim, Stephen, Lejeune, Nicolas, O'Brien, Anthony T., Bodart, Olivier, Laureys, Steven, Thibaut, Aurore, and Chatelle, Camille
- Subjects
- *
CONSCIOUSNESS disorders , *TREATMENT effectiveness , *PHYSICAL therapy , *PAIN management , *TREATMENT programs , *PERSISTENT vegetative state , *VISCERAL pain , *RESEARCH , *PAIN measurement , *ANALGESICS , *RESEARCH methodology , *SENSORY perception , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *BLIND experiment , *CONSCIOUSNESS - Abstract
Abstract: Neuro-orthopedic disorders are common in patients with disorders of consciousness (DOC) and can lead to potential pain. However, the patients' inability to communicate makes pain detection and management very challenging for clinicians. In this crossover randomized double-blind placebo-controlled study, we investigated the effects of an analgesic treatment on the presence of nociception-related behaviors. At baseline, the Nociception Coma Scale-Revised (NCS-R) was performed in 3 conditions: a non-noxious stimulation, a noxious stimulation, and during a physiotherapy session. Patients with a NCS-R total score during physiotherapy equal or above the score observed after the noxious stimulation could participate to the clinical trial, as well as patients with a score above 5. They received an analgesic treatment and a placebo on 2 consecutive days in a randomized order followed by an assessment with the NCS-R. Of the 18 patients, 15 displayed signs of potential pain during physiotherapy. Patients showed higher NCS-R scores during physiotherapy compared with the other conditions, suggesting that mobilizations were potentially painful. Of these 15 patients, 10 met the criteria to participate in the placebo-controlled trial. We did not find any effect of analgesic treatment on the NCS-R scores. This study highlights that physiotherapy may be potentially painful for patients with DOC, while analgesic treatments did not reduced NCS-R scores. Therefore, careful monitoring with appropriate assessment and treatment before and during mobilization should become a priority in clinical settings. Future studies should focus on the development of assessment tools sensitive to analgesic dosage to manage pain in DOC. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
43. Effects of exercise on symptoms of anxiety in primary care patients: A randomized controlled trial.
- Author
-
Henriksson, Malin, Wall, Alexander, Nyberg, Jenny, Adiels, Martin, Lundin, Karin, Bergh, Ylva, Eggertsen, Robert, Danielsson, Louise, Kuhn, H. Georg, Westerlund, Maria, David Åberg, N., Waern, Margda, and Åberg, Maria
- Subjects
- *
PRIMARY care , *RANDOMIZED controlled trials , *SYMPTOMS , *EXERCISE therapy , *RESISTANCE training , *ANXIETY treatment , *ANXIETY disorders treatment , *RESEARCH , *RESEARCH methodology , *EVALUATION research , *PRIMARY health care , *TREATMENT effectiveness , *COMPARATIVE studies , *PSYCHOLOGICAL tests , *QUALITY of life , *MENTAL depression , *EXERCISE - Abstract
Background: There is a need for high-quality research regarding exercise interventions for persons with anxiety disorders. We investigate whether a 12-week exercise intervention, with different intensities, could reduce anxiety symptoms in patients with anxiety disorders.Methods: 286 patients were recruited from primary care in Sweden. Severity of symptoms was self-assessed using the Beck Anxiety Inventory (BAI) and the Montgomery Åsberg Depression Rating Scale (MADRS-S). Participants were randomly assigned to one of two group exercise programs with cardiorespiratory and resistance training and one control/standard treatment non-exercise group, with 1:1:1 allocation.Results: Patients in both exercise groups showed larger improvements in both anxiety and depressive symptoms compared to the control group. No differences in effect sizes were found between the two groups. To study a clinically relevant improvement, BAI and MADRS-S were dichotomized with the mean change in the control group as reference. In adjusted models the odds ratio for improved symptoms of anxiety after low-intensity training was 3.62 (CI 1.34-9.76) and after moderate/high intensity 4.88 (CI 1.66-14.39), for depressive symptoms 4.96 (CI 1.81-13.6) and 4.36 (CI 1.57-12.08) respectively. There was a significant intensity trend for improvement in anxiety symptoms.Limitations: The use of self-rating measures which bears the risk of an under- or overestimation of symptoms.Conclusions: A 12-week group exercise program proved effective for patients with anxiety syndromes in primary care. These findings strengthen the view of physical exercise as an effective treatment and could be more frequently made available in clinical practice for persons with anxiety issues. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
44. A peer learning intervention in workplace introduction - managers' and new graduates' perspectives.
- Author
-
Pålsson, Ylva, Engström, Maria, Swenne, Christine Leo, and Mårtensson, Gunilla
- Subjects
- *
AFFINITY groups , *WELL-being , *STATISTICS , *NURSE administrators , *NURSES' attitudes , *EVALUATION of human services programs , *NURSING , *RESEARCH methodology , *INTERVIEWING , *GRADUATES , *LEARNING strategies , *EMPLOYEE orientation , *RANDOMIZED controlled trials , *SELF-efficacy , *T-test (Statistics) , *QUESTIONNAIRES , *JOB satisfaction , *RESEARCH funding , *STATISTICAL sampling , *DATA analysis , *DATA analysis software - Abstract
Background: Evaluation of a complex intervention are often described as being diminished by difficulties regarding acceptability, compliance, delivery of the intervention, recruitment and retention. Research of peer learning for nursing students have found several positive benefits while studies of peer learning for newly graduated nurses are lacking. This study aimed (1) to investigate the study process in terms of (a) first-line managers' perspectives on the intervention study, the difficulties they face and how they handle these and (b) new graduates' fidelity to the intervention and (2) to examine the effect of the peer learning intervention in workplace introduction for newly graduated nurses. Methods: A mixed-methods approach using semi-structured interviews with eight managers, repeated checklist for fidelity and questionnaires conducted with 35 new graduates from June 2015 and January 2018, whereof 21 in the intervention group. The peer learning intervention's central elements included pairs of new graduates starting their workplace introduction at the same time, working the same shift and sharing responsibility for a group of patients for 3 weeks. The intervention also included 3 months of regular peer reflection. Results: Managers offered mostly positive descriptions of using peer learning during workplace introduction. The intervention fidelity was generally good. Because of recruitment problems and thereby small sample size, it was difficult to draw conclusions about peer learning effects and, thus, the study hypothesis could either be accepted or rejected. Thereby, the study should be regarded as a pilot. Conclusions: The present study found positive experiences of, from managers, and fidelity to the peer learning intervention; regarding the experimental design, there were lessons learned. Trial registration: Before starting data collection, a trial registration was registered at (Trial ID ISRCTN14737280). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Peanuts or an Isocaloric Lower Fat, Higher Carbohydrate Nighttime Snack Have Similar Effects on Fasting Glucose in Adults with Elevated Fasting Glucose Concentrations: a 6-Week Randomized Crossover Trial.
- Author
-
Sapp, Philip A, Kris-Etherton, Penny M, and Petersen, Kristina S
- Subjects
- *
CROSSOVER trials , *CARDIOVASCULAR diseases risk factors , *PEANUTS , *CARBOHYDRATES , *FAT , *FOOD habits , *MILKFAT , *FASTING , *SNACK foods , *RESEARCH , *RESEARCH methodology , *BLOOD sugar , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *RESEARCH funding , *GLUCOSE , *CARDIOVASCULAR disease diagnosis - Abstract
Background: The glycemic effects of peanuts are not well studied and no trials have been conducted in adults with elevated fasting plasma glucose (FPG). Furthermore, intake of peanuts as a nighttime snack, an eating occasion affecting FPG, has not been examined.Objectives: The aim was to determine the effect of consuming 28 g/d of peanuts as a nighttime snack for 6 wk on glycemic control and cardiovascular disease risk factors, compared with an isocaloric lower fat, higher carbohydrate (LFHC) snack (whole grain crackers and low-fat cheese), in adults with elevated FPG.Methods: In a randomized crossover trial, 50 adults (FPG 100 ± 8 mg/dL) consumed dry roasted, unsalted peanuts [164 kcal; 11% energy (E) carbohydrate, 17% E protein, and 73% E fat] or a LFHC snack (164 kcal; 54% E carbohydrate, 17% E protein, and 33% E fat) in the evening (after dinner and before bedtime) for 6 wk with a 4-wk washout period. Primary (FPG) and secondary end points [Healthy Eating Index-2015 (HEI-2015), weight, insulin, fructosamine, lipids/lipoproteins, central and peripheral blood pressure, and pulse wave velocity] were evaluated at the beginning and end of each condition. Linear mixed models were used for data analysis.Results: FPG was not different between the peanut and LFHC conditions (end point mean difference: -0.6 mg/dL; 95% CI: -2.7, 1.6; P = 0.67). There were no between-condition effects for secondary cardiometabolic endpoints. The HEI-2015 score was not different between the conditions (3.6 points; P = 0.19), although the seafood/plant protein (2.0 points; P < 0.01) and added sugar (0.8 points; P = 0.04) components were improved following peanut intake. The whole grain component was lower with peanuts compared with LFHC (-2.6 points; P < 0.01).Conclusions: In adults with elevated FPG, peanuts as a nighttime snack (28 g/d) did not affect FPG compared with an isocaloric LFHC snack after 6 wk.This trial was registered at clinicaltrials.gov as NCT03654651. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
46. Intermittent theta burst stimulation of cerebellar vermis enhances fronto-cerebellar resting state functional connectivity in schizophrenia with predominant negative symptoms: A randomized controlled trial.
- Author
-
Basavaraju, Rakshathi, Ithal, Dhruva, Thanki, Milind Vijay, Ramalingaiah, Arvinda Hanumanthapura, Thirthalli, Jagadisha, Reddy, Rajakumari P., Brady, Roscoe O., Halko, Mark A., Bolo, Nicolas R., Keshavan, Matcheri S., Pascual-Leone, Alvaro, Mehta, Urvakhsh Meherwan, Kesavan, Muralidharan, and Brady, Roscoe O Jr
- Subjects
- *
SYMPTOMS , *FUNCTIONAL connectivity , *PREFRONTAL cortex , *RANDOMIZED controlled trials , *TRANSCRANIAL magnetic stimulation , *AUDITORY hallucinations , *SCHIZOPHRENIA treatment , *FRONTAL lobe , *RESEARCH , *SCHIZOPHRENIA , *RESEARCH methodology , *EVALUATION research , *CEREBELLUM , *COMPARATIVE studies , *RESEARCH funding - Abstract
Objective: Negative symptoms of schizophrenia are substantially disabling and treatment resistant. Novel treatments like repetitive transcranial magnetic stimulation (TMS) need to be examined for the same using the experimental medicine approach that incorporates tests of mechanism of action in addition to clinical efficacy in trials.Methods: Study was a double-blind, parallel, randomized, sham-controlled trial recruiting schizophrenia with at least a moderate severity of negative symptoms. Participants were randomized to real or sham intermittent theta burst stimulation (iTBS) under MRI-guided neuro-navigation, targeting the cerebellar vermis area VII-B, at a stimulus intensity of 100% active motor threshold, two sessions/day for five days (total = 6000 pulses). Assessments were conducted at baseline (T0), day-6 (T1) and week-6 (T2) after initiation of intervention. Main outcomes were, a) Scale for the Assessment of Negative Symptoms (SANS) score (T0, T1, T2), b) fronto-cerebellar resting state functional connectivity (RSFC) (T0, T1).Results: Thirty participants were recruited in each arm. Negative symptoms improved in both arms (p < 0.001) but was not significantly different between the two arms (p = 0.602). RSFC significantly increased between the cerebellar vermis and the right inferior frontal gyrus (pcluster-FWER = 0.033), right pallidum (pcluster-FWER = 0.042) and right frontal pole (pcluster-FWER = 0.047) in the real arm with no change in the sham arm.Conclusion: Cerebellar vermal iTBS engaged a target belonging to the class of cerebello-subcortical-cortical networks, implicated in negative symptoms of schizophrenia. However, this did not translate to a superior clinical efficacy. Future trials should employ enhanced midline cerebellar TMS stimulation parameters for longer durations that can potentiate and translate biological changes into clinical effects. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
47. Tincture of Time: The Evolution of Goals in Adolescents and Young Adults with Cancer.
- Author
-
Steineck, Angela, Barton, Krysta S., Bradford, Miranda C., Yi-Frazier, Joyce P., and Rosenberg, Abby R.
- Subjects
- *
RESEARCH methodology , *HEALTH status indicators , *MENTAL health , *CANCER patients , *RANDOMIZED controlled trials , *QUALITY of life , *STATISTICAL sampling , *CONTENT analysis , *HOBBIES , *ONCOLOGY , *GOAL (Psychology) - Abstract
Purpose: A diagnosis of cancer often derails an individual's goals. The purpose of this mixed-methods analysis was to describe the evolution of adolescent and young adult (AYA)-reported goals in the year after a diagnosis of new or advanced cancer. Methods: As part of the Promoting Resilience in Stress Management (PRISM) phase 2 randomized controlled trial, AYAs with cancer (ages 12–25 years) were asked at baseline, 6 months, and 12 months: "Please give an example of a goal you hope to accomplish over the next month/year." We used content analysis to categorize goals as follows: life milestones, physical health, mental/emotional health, cancer specific, and hobbies/interests. We summarized goal categories at each time point: for the entire cohort, by baseline diagnosis status (new vs. advanced cancer), treatment status (on-therapy vs. off-therapy), and baseline health-related quality of life (high vs. low). Results: Eighty-six participants completed the study and were included in the analysis (control: n = 41, PRISM: n = 45); 69 reported their goals at 6 months, and 54 at 12 months. Participants submitted a total of 169 goals at baseline, 148 at 6 months, and 126 at 12 months. At baseline, cancer-specific goals were most common for the short-term (35%), whereas milestone goals were most common for the long-term (46%). At 6 months, milestone goals were most common in both short- (38%) and long-term (51%) categories. A similar pattern was seen at 12 months. Conclusion: AYAs' goals change over the first year of their cancer experience, with a shift in short-term goals from cancer-specific goals at baseline to milestone goals at later time points. ClinicalTrials.gov (NCT02340884). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. A Novel Group Parenting Intervention for Emotional and Behavioral Difficulties in Young Autistic Children: Autism Spectrum Treatment and Resilience (ASTAR): A Randomized Controlled Trial.
- Author
-
Charman, Tony, Palmer, Melanie, Stringer, Dominic, Hallett, Victoria, Mueller, Joanne, Romeo, Renee, Tarver, Joanne, Paris Perez, Juan, Breese, Lauren, Hollett, Megan, Cawthorne, Thomas, Boadu, Janet, Salazar, Fernando, O'Leary, Mark, Beresford, Bryony, Knapp, Martin, Slonims, Vicky, Pickles, Andrew, Scott, Stephen, and Simonoff, Emily
- Subjects
- *
AUTISTIC children , *AUTISM in children , *RANDOMIZED controlled trials , *PARENTING , *CHILD care workers , *NEOPHOBIA , *RESEARCH , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *AUTISM , *RESEARCH funding , *EMOTIONS , *PARENTS - Abstract
Objective: To examine the feasibility and preliminary efficacy of a group behavioral parenting intervention for emotional and behavioral problems (EBPs) in young autistic children.Method: This was a feasibility pilot randomized controlled trial comparing a 12-week group behavioral parenting intervention (Predictive Parenting) to an attention control (Psychoeducation). Parents of 62 autistic children 4 to 8 years of age were randomized to Predictive Parenting (n = 31) or Psychoeducation (n = 31). The primary outcome was a blinded observational measure of child behaviors that challenge. Secondary outcomes were observed child compliance and parenting behaviors; parent- and teacher-reported child EBPs; self-reported parenting practices, stress, self-efficacy, and well-being. Cost-effectiveness was also explored.Results: Recruitment, retention, completion of measures, treatment fidelity, and parental satisfaction were high for both interventions. There was no group difference in primary outcome: mean log of rate 0.18 lower (d, 90% CI = -0.44 to 0.08) in Predictive Parenting. Differences in rates of child compliance (0.44, 90% CI = 0.11 to 0.77), facilitative parenting (0.63, 90% CI = 0.33 to 0.92) and parent-defined target symptom change (-0.59, 90% CI -0.17 to -1.00) favored Predictive Parenting. There were no differences on other measures. Predictive Parenting was more expensive than Psychoeducation, with a low probability of being more cost-effective.Conclusion: Feasibility was demonstrated. There was no evidence from this pilot trial that Predictive Parenting resulted in reductions in child EBPs beyond those seen following Psychoeducation; in addition, the effect size was small, and it was more expensive. However, it showed superiority for child compliance and facilitative parenting with moderate effect sizes. Future, definitive studies should evaluate whether augmented or extended intervention would lead to larger improvements.Clinical Trial Registration Information: Autism Spectrum Treatment and Resilience (ASTAR); https://www.isrctn.com/; 91411078. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
49. Effectiveness of shared decision-making intervention in patients with lumbar degenerative diseases: A randomized controlled trial.
- Author
-
Chen, Chia-Hsien, Kang, Yi-No, Chiu, Po-Yao, Huang, Yi-Jing, Elwyn, Glyn, Wu, Meng-Huang, Kang, Jiunn-Horng, Hou, Wen-Hsuan, and Kuo, Ken N
- Subjects
- *
DEGENERATION (Pathology) , *RANDOMIZED controlled trials , *DECISION making , *EDUCATIONAL standards , *HEALTH education , *RESEARCH , *PATIENT participation , *RESEARCH methodology , *CLINICS , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *COMMUNICATION - Abstract
Objective: To evaluate the efficacy of shared decision-making (SDM) intervention among patients with lumbar degenerative diseases (LDDs) in terms of decision self-efficacy, control preferences, SDM process, decision satisfaction, and conflict.Methods: A total of 130 outpatients with LDDs recruited from orthopedic or rehabilitation clinics were randomly assigned to the SDM intervention (n = 67) or comparison (n = 63) groups. Patients in the intervention group received decision aids (DAs) with decision coaching and those in controlled group received standard educational materials from a health educator. The primary outcome was decision self-efficacy, and secondary outcomes were control preference, SDM process, conflict, and satisfaction.Results: The SDM intervention significantly improved decision self-efficacy (mean difference [MD] = 7.1, 95% confidence interval [CI]: 1.7-12.5, partial η2 = 0.05) and reduced conflict (MD = -7.0, 95% CI: -12.2 to -1.9, partial η2 = 0.06), especially in patients without family involvement, compared with the health education group. However, no significant between-group differences were observed in other outcomes.Conclusion: SDM intervention improved SDM self-efficacy and reduced conflict in patients with LDDs.Practice Implications: Clinicians can integrate DAs and decision coaching in SDM conversations. SDM intervention seems to engage patients in decision-making, especially those without family involvement. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
50. The ultra-long study: a randomized controlled trial evaluating long-term GnRH downregulation prior to ART in women with endometriosis.
- Author
-
Tomassetti, C, Beukeleirs, T, Conforti, A, Debrock, S, Peeraer, K, Meuleman, C, and D'Hooghe, T
- Subjects
- *
INDUCED ovulation , *RANDOMIZED controlled trials , *ENDOMETRIOSIS , *MEDICAL research , *MEDICAL sciences , *DEVELOPMENTAL biology , *BIOCHEMISTRY , *RESEARCH , *BIRTH rate , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *INFERTILITY , *PHENOMENOLOGY , *COMPARATIVE studies , *RESEARCH funding , *FERTILIZATION in vitro - Abstract
Study Question: Does ultra-long downregulation with a GnRH agonist (triptorelin depot) in previously operated patients with endometriosis improve the rate of clinical pregnancy with positive fetal heart beat (CPHB) in the subsequent initiated fresh ART cycle?Summary Answer: Ultra-long downregulation with a GnRH agonist prior to ART did not improve the rate of CPHB in the subsequent fresh ART cycle in previously completely operated patients but the trial was underpowered due to early termination.What Is Known Already: Administration of GnRH agonists for a period of 3-6 months prior to ART in women with endometriosis may increase the odds of clinical pregnancy. However, the quality of the studies on which this statement is based is questionable, so these findings need confirmation.Study Design, Size, Duration: A controlled, randomized, open label trial was performed between 1 June 2013 and 31 December 2016 (start and end of recruitment, respectively). Patients with prior complete laparoscopic treatment of any type or stage of endometriosis and an indication for ART were randomized (by a computer-generated allocation sequence) into two groups: the control group underwent ART stimulation in a classical long agonist protocol using preparation with oral contraceptives, the ultra-long group first underwent at least 3 months downregulation followed by a long agonist protocol for ART stimulation. The sample size was calculated to detect a superiority of the ultra-long downregulation protocol, based on the hypothesis that baseline CPHB rate in the control group of 20% would increase to 40% in the ultra-long group. For a power of 20% at a significance level of 5%, based on two-sided testing, including 5% of patients lost to follow-up, the necessary sample size was 172 patients (86 per group).Participants/materials, Setting, Methods: This trial was conducted at the Leuven University Fertility Center, a tertiary care center for endometriosis and infertility, and a total of 42 patients were randomized (21 in the control group and 21 in the ultra-long group).Main Results and the Role Of Chance: Baseline characteristics were similar in both groups. The primary outcome studied-CPHB after the initiated ART treatment-did not differ and was 25% (5/20) in the control group, and 20% (4/20) in the ultra-long group (P > 0.999; relative risk (RR) 1.25, 95% CI 0.41-3.88). Cumulative (fresh + associated frozen) CPHB rates were also similar in the control versus ultra-long group (8/20, 40% vs 6/20, 30%, P = 0.7411; RR = 1.33, 95% CI 0.57-3.19). When other secondary outcomes were compared with the ultra-long group, patients from the control group had a shorter duration of stimulation (mean 11.8 days (SD ± 2.4) versus 13.2 days (SD ± 1.5), P = 0.0373), a lower total dose of gonadotrophins used (mean 1793 IU/d (SD ± 787) vs 2329 (SD ± 680), P = 0.0154), and a higher serum estradiol concentration (ng/ml) at the end of ovarian stimulation on the day of ovulation triggering or cycle cancellation (mean1971 (SD ± 1495) vs 929 (± 548); P = 0.0326), suggesting a better ovarian response in the control group.Limitations, Reasons For Caution: Due to a strong patient preference, nearly exclusively against ultra-long downregulation (even though patients were thoroughly informed of the potential benefits), the targeted sample size could not be achieved and the trial was stopped prematurely.Wider Implications Of the Findings: Conditional power analysis revealed that the probability of confirming the study hypothesis if the study were completed would be low. We hypothesize that in patients with prior complete surgical treatment of endometriosis, the ultra-long protocol does not enhance ART-CPHB rates. Patient's concerns and preferences regarding possible side-effects, and delay of ART treatment start with the ultra-long protocol should be taken into account when considering this type of treatment in women with endometriosis.Study Funding/competing Interest(s): C.T. was during 2 years funded by a grant from the Clinical research Foundation of UZ Leuven (KOF) and during 2 years by the Research Foundation-Flanders (FWO grant number: 1700816N). C.T. reports grants from Clinical Research Foundation of the University Hospitals of Leuven (KOF), grants from Fund for Scientific Research Flanders (FWO), during the conduct of the study; grants, non-financial support and other from Merck SA, non-financial support and other from Gedeon Richter, non-financial support from Ferring Pharmaceuticals, outside the submitted work. T.D. is vice president and head of Global Medical Affairs Fertility, Research and Development, Merck KGaA, Darmstadt, Germany. He is also a professor in Reproductive Medicine and Biology at the Department of Development and Regeneration, Group Biomedical Sciences, KU Leuven (University of Leuven), Belgium and an adjunct professor at the Department of Obstetrics and Gynecology in the University of Yale, New Haven, USA. Neither his corporate role nor his academic roles represent a conflict of interest with respect to the work done by him for this study. A.C. reports personal fees from Merck S.p.A., outside the submitted work. The other co-authors have no conflict of interest.Trial Registration Number: UZ Leuven trial registry SS55300, EudraCT number 2013-000993-32, clinicaltrials.gov NCT02400801.Trial Registration Date: Registration for EudraCT on 1 March 2013.Date Of First Patient’s Enrolment: 4 September 2013. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.